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EXPERIMENTAL EXECUTION
Seema K. Shah *
Abstract: On July 23, 2014, an execution in Arizona lasted nearly two hours, with the
inmate struggling to breathe and gasping over 600 times, according to a local reporter
witnessing the execution. This was the third example of a botched execution in seven
months. The Supreme Court last evaluated the constitutionality of execution by lethal
injection in 2008, but did not provide a clear standard for evaluating risks. Since that time,
the lethal injection landscape has transformed. States are using entirely new drugs and drug
combinations, and sometimes obtain these drugs from questionable sources, making it hard to
predict what will happen in any given execution. The Court has now granted certiorari to
examine the constitutionality of Oklahoma’s lethal injection protocol in the case of Glossip v.
Gross.
Although it is increasingly common to refer to lethal injection executions as
experimental, this Article is the first to conduct a rigorous analysis of whether and to what
extent executions by lethal injection involve the conduct of research and therefore should be
analyzed under the ethical and regulatory framework that governs biomedical research. I
argue that an important factor driving this high error rate is that the use of novel drugs, drug
combinations, and dosages in lethal injection executions is a type of research. More
specifically, it is poorly designed experimentation that is not based on evidence. If the death
penalty is justified, individual inmates are being exposed to uncertain (and sometimes
unnecessary) risks in order to obtain benefits for others by furthering the underlying aims of
capital punishment.
This insight suggests three important conclusions. First, states should draw from existing
scholarship on ethics and regulations that apply to biomedical research with captive and
vulnerable populations. Prisoners are considered a vulnerable population, and experimental
executions involving prisoners should abide by the general principles that are applicable to
research: respect for autonomy, non-maleficence, and justice. Second, legal safeguards that
follow from these principles should be applied to executions—in particular, states should ask
for informed consent from prisoners to modifications of lethal injection protocols, obtain
independent review by a regulatory body like the Food and Drug Administration, and apply a
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standard requiring risk minimization in the choice of drugs and procedures. Finally, states
should systematically gather data as they engage in experimental execution.
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INTRODUCTION
An execution in Oklahoma went terribly awry on April 28, 2014. 1
Oklahoma was administering a new execution protocol that used the
drug midazolam, a sedative that is often used in combination with other
anesthetic agents. 2 Oklahoma had never used this drug in executions
before; in fact, only a few states had any experience with using the drug
in lethal injections.3 Florida had previously used this drug in lethal
injections, but with a dose five times higher than what was indicated in
Oklahoma’s protocol. 4 If the execution had gone as planned, Clayton
Lockett would have first received midazolam; been declared
1. Helen Pow, Execution Horribly Botched in Oklahoma, DAILY MAIL (Apr. 29, 2014),
http://www.dailymail.co.uk/news/article-2615631/Oklahoma-prepares-execute-2-inmates.html.
2. Manufacturer’s Drug Catalog for Midazolam, SAGENT PHARMACEUTICALS (2014),
http://www.sagentpharma.com/Products/Midazolam/Catalog/Midazolam_Catalog.pdf.
3. Pow, supra note 1.
4. Id.
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unconscious;
then
received
vecuronium
bromide
(a
paralytic/neuromuscular blocking agent that would restrict his
movements); and finally received potassium chloride (the drug likely to
end his life). 5 A few minutes after a prison official declared him
unconscious, Lockett mumbled statements including the word, “man.” 6
He “began breathing heavily, writhing, clenching his teeth and straining
to lift his head off the pillow.” 7 Prison officials then blocked the
witnesses from observing the rest of the proceedings. 8 The Department
of Corrections then called off the execution and unsuccessfully tried to
resuscitate Lockett, and Lockett eventually died of a heart attack
approximately forty-five minutes after the execution began. 9 Although a
Department of Corrections official stated that Lockett’s veins
“exploded,” 10 an autopsy examination performed by a forensic
pathologist hired by death row inmates appears to contradict official
reports. 11 Prison officials claimed that they had to inject the drugs into
Lockett’s femoral vein, located in his groin, which is riskier and more
difficult than using more common injection sites. 12 However, the
autopsy report contradicts this claim, finding that Lockett’s surface and
deep veins had “excellent” integrity. 13 Another execution scheduled to
occur that same night was stayed for several months, pending an
investigation into Mr. Lockett’s execution, but took place on January 15,
2015. 14 Clayton Lockett’s estate has brought suit against the State of
5. OKLA. STATE PENITENTIARY, OSP 040301-01, PROCEDURES FOR THE EXECUTION OF
OFFENDERS
SENTENCED
TO
DEATH
(2014),
available
at
http://bloximages.newyork1.vip.townnews.com/tulsaworld.com/content/tncms/assets/v3/editorial/e/
37/e3763982-d19c-11e3-addc-0017a43b2370/5362fb4c11d06.pdf.pdf; see also State-by-State
PENALTY
INFO.
CTR.,
Lethal
Injection
Information,
Oklahoma,
DEATH
http://www.deathpenaltyinfo.org/state-lethal-injection (last visited Jan. 5, 2015).
6. Greg Botelho & Dana Ford, Oklahoma Stops Execution After Botching Drug Delivery; Inmate
Dies, CNN (Oct. 9, 2014, 2:55 PM), http://www.cnn.com/2014/04/29/us/oklahoma-botchedexecution/index.html.
7. Pow, supra note 1.
8. Id.
9. Michael Muskal, Private Autopsy Blames Oklahoma for Botched Execution, L.A. TIMES (June
13,
2014),
http://www.latimes.com/nation/nationnow/la-na-nn-autopsy-botched-oklahomaexecution-20140613-story.html; Michele Richinick, White House Weighs in on Botched Oklahoma
Execution, MSNBC (Apr. 30, 2014, 8:23 AM), http://www.msnbc.com/morning-joe/oklahomagovernor-lockett-botched-execution.
10. Botelho & Ford, supra note 6
11. Muskal, supra note 9.
12. Id.
13. Id.
14. Josh Sanburn, Oklahoma Executes First Inmate Since Botched Lethal Injection in April, TIME
(Jan. 15, 2015), http://time.com/3669126/oklahoma-lethal-injection-execution-charles-warner-
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Oklahoma and a physician alleged to have been involved in the
execution, claiming violations of the Eighth Amendment to the U.S.
Constitution, international law, and human decency. 15 Meanwhile,
Oklahoma has already modified the state’s protocol by increasing the
dose of midazolam that will be administered to inmates in future
executions. 16
More recently, on July 23, 2014, the execution of Joseph Wood in
Arizona lasted for nearly two hours, with the inmate struggling to
breathe and gasping over 600 times, according to a local reporter
witnessing the execution. 17 As the reporter described it: “The movement
was like a piston: The mouth opened, the chest rose, the stomach
convulsed . . . .” 18 Arizona used two drugs, hydromorphone and
midazolam, 19 which had previously been used in a botched execution in
Ohio in January 2014. 20 The execution log reveals that Wood was
injected with the drugs fifteen times in 114 minutes. 21 In the middle of
clayton-lockett/; see also Katie Zezima, Okla. Attorney General Seeks Execution Delay Following
Botched Lethal Injection, WASH. POST (May 8, 2014), http://www.washingtonpost.com/blogs/postpolitics/wp/2014/05/08/okla-attorney-general-seeks-execution-delay-following-botched-lethalinjection.
15. Complaint at 1–2, Lockett v. Fallin, No. 5:2014-cv-01119-HE (W.D. Okla. Oct. 13, 2014)
(arguing that “[d]espite innumerable treaties, protocols and accepted norms of human decency
prohibiting human experimentation on unwilling subjects, while cast in the unwitting role of human
lab rat for the Defendants, Clayton Lockett was administered an untested mixture of drugs that had
not previously been used for executions in the United States”). The ACLU and news organizations
have also filed suit since reporters were not allowed to observe the entire Lockett execution. See
Lawsuit Seeks Uncensored Access to Executions, Citing First Amendment Press Freedom, ACLU
(Aug. 25, 2014), https://www.aclu.org/free-speech/aclu-and-news-organizations-sue-over-closedblinds-during-botched-lockett-execution.
16. Erik Eckholm, Oklahoma Executes First Inmate Since Slipshod Injection in April, N.Y. TIMES
(Jan. 15, 2015), http://www.nytimes.com/2015/01/16/us/oklahoma-execution-charles-warner-lethalinjection.html?_r=2; see also Josh Sanburn, Ohio Ups Lethal-Injection Dosages After Controversial
Execution, TIME (Apr. 28, 2014), http://time.com/80092/ohio-lethal-injection-dosages-execution.
17. Fernanda Santos & John Schwartz, A Prolonged Execution in Arizona Leads to a Temporary
Halt, N.Y. TIMES (July 24, 2014), http://www.nytimes.com/2014/07/25/us/a-prolonged-executionin-arizona-leads-to-a-temporary-halt.html?_r=0.
18. Mark Kiefer, Reporter Describes Arizona Execution, ARIZ. REPUBLIC (July 26, 2014),
http://www.azcentral.com/story/news/arizona/politics/2014/07/24/arizona-execution-joseph-woodeyewitness/13083637/.
19. Santos & Schwartz, supra note 17.
20. Ohio to Increase Lethal Injection Drug Dosages After Execution Leads to Lawsuit, THE
GUARDIAN (Apr. 28, 2014, 5:45 PM), http://www.theguardian.com/world/2014/apr/28/ohioincrease-lethal-drug-dosages.
21. Mark Berman, The Prolonged Arizona Execution Used 15 Doses of Lethal Injection Drugs,
WASH. POST (Aug. 4, 2014), http://www.washingtonpost.com/news/post-nation/wp/2014/08/04/theprolonged-arizona-execution-used-15-doses-of-lethal-injection-drugs/. The execution log has been
made available here: http://www.scribd.com/doc/235854026/Joseph-Wood-execution-log.
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the execution, attorneys for Mr. Wood filed an emergency appeal to a
federal district court to stop it.22 The transcript of this appeal reveals a
great deal of confusion, with the state attorney general initially stating
that Wood was brain dead, even though he was still breathing
independently—a medical impossibility. 23 The court was not convinced
that stopping the execution would eliminate pain or suffering given that
the inmate’s heart rate was slowing, and was also concerned that
stopping the execution might do more harm than good. 24 Mr. Wood was
declared dead before the hearing concluded. 25 The governor of Arizona,
Jan Brewer, has announced that an investigation will be conducted into
Wood’s execution, while expressing that eyewitness and media reports
indicated that he did not suffer. 26
These examples are illustrative of a larger problem facing executions
by lethal injection—the predominant method of execution used in the
United States. 27 A recent study has estimated that seven percent of all
lethal injection executions have involved serious errors, which is a
higher rate of failure than any other method of execution. 28
Commentators have begun to argue that when executions by lethal
injection try out unproven drugs and novel procedures for use on nonconsenting inmates, lethal injection resembles “a nationwide,
government-sponsored clinical trial” 29 that raises ethical and regulatory
concerns and violates international legal norms. 30 Following the Lockett
execution, a group of inmates in Oklahoma filed a lawsuit arguing that

22. Kiefer, supra note 18.
23. Transcript of Telephonic Motion for Emergency Stay of Execution at 7–8, Wood v. Ryan,
No. CV 14-1447-PHX-NVW (D. Ariz. July 23, 2014), available at http://www.scribd.com/doc/
234993495/Transcript-related-to-Joseph-Wood-execution.
24. Id. at 15–18.
25. Id. at 16.
26. Jacob Gershman, Arizona Inmate Dies 2 Hours After Start of Execution, WALL ST. J. (July 24,
2014, 7:11 AM), http://www.wsj.com/articles/arizona-inmate-joseph-rudolph-wood-dies-2-hoursafter-start-of-execution-1406159321.
27. Deborah W. Denno, Lethal Injection Chaos Post-Baze, 102 GEO. L.J. 1331, 1342–43 (2014).
28. AUSTIN SARAT ET AL., GRUESOME SPECTACLES: BOTCHED EXECUTIONS AND AMERICA’S
DEATH PENALTY 120, app. A at 177 (2014).
29. Jeff Stryker, Lethal Injections: Medicine and Research, HASTINGS CTR. REP., Jan.–Feb. 2008,
at 53.
30. Johnny Holschuh, Experimenting with Death: Baze v. Rees, the Execution of Dennis
McGuire, and the Constitutionality of Experimenting with Lethal Injection Drugs, U. CIN. L. REV.
BLOG (May 13, 2014), http://uclawreview.org/2014/05/13/experimenting-with-death-baze-v-reesthe-execution-of-dennis-mcguire-and-the-constitutionality-of-experimenting-with-lethal-injectiondrugs/.
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lethal injection involves unconstitutional experimentation on prisoners. 31
Although it is increasingly common to refer to lethal injection
executions as experimental, 32 this Article is the first to conduct a
rigorous analysis of whether and to what extent executions by lethal
injection involve the conduct of research and therefore should be
analyzed under the ethical and regulatory framework that governs
biomedical research.
In this Article, I argue that it is theoretically helpful to understand
recent changes to execution protocols as a kind of biomedical research.
By trying novel drugs, drug combinations, and dosages to see if they
will work, states are conducting a type of biomedical research—namely,
research that is poorly designed and not based in evidence. Although
each execution involves changes that affect only one inmate, states make
changes after botched executions and try to improve their protocols to
use on other inmates on death row. There are several different
regulations governing research, some promulgated by federal agencies
(like the Department of Health and Human Services (DHHS), the
Bureau of Prisons, and the Food and Drug Administration (FDA)), and
also state statutes on research on prisoners. These regulations define
research very differently. Not all regulations will cover this type of
research, but state statutes and FDA regulations have broad enough

31. Katie Fretl, Oklahoma Inmates File Lawsuit over “Unconstitutional” Executions, THE
GUARDIAN (June 25, 2014, 3:39 PM), http://www.theguardian.com/world/2014/jun/25/oklahomadeath-row-inmates-file-lawsuit-unconstitutional-executions (“The plaintiffs are not challenging their
convictions or sentences of death in this action, . . . . They are challenging only the way in which
their sentences of death will be carried out by the defendants.” (internal quotations omitted)).
32. See, e.g., In re Ohio Execution Protocol Litig., 994 F. Supp. 2d 906, 913 (S.D. Ohio 2014)
(“There is absolutely no question that Ohio’s current protocol presents an experiment in lethal
injection processes. The science involved, the new mix of drugs employed at doses based on theory
but understandably lacking actual application in studies, and the unpredictable nature of human
response make today’s inquiry at best a contest of probabilities.”); JOHNS HOPKINS CLINIC FOR PUB.
HEALTH LAW & POLICY, STATE DEPARTMENTS OF CORRECTIONS ARE VIOLATING FDA’S
INVESTIGATIONAL NEW DRUG REGULATIONS BY EXPERIMENTING WITH LETHAL INJECTION DRUGS
(2014), available at http://www.jhsph.edu/research/centers-and-institutes/center-for-law-and-thepublics-health/Lethal%20Injection%20Policy%20Paper%20Final.pdf; Leonard G. Koniaris et al.,
Ethical Implications of Modifying Lethal Injection Protocols, 5 PLOS MED. 845 (2008); Seema K.
Shah, How Lethal Injection Reform Constitutes Impermissible Research on Prisoners, 45 AM.
CRIM. L. REV. 1101 (2008); Della Hasselle, Lawyers Argue that Next Week’s Execution Could
Amount to “Human Experimentation,” THE LENS (Jan. 28, 2014), http://thelensnola.org/2014/
01/28/lawyers-argue-that-next-weeks-execution-could-amount-to-human-experimentation/; Sarah
Lazare, “Experimenting” on a Death Row Inmate: Florida to Execute Man by Untested Drug,
COMMON DREAMS (Oct. 15, 2014), http://www.commondreams.org/news/2013/10/15/
experimenting-death-row-inmate-florida-execute-man-untested-drug; Ruth Macklin, Is Execution by
Lethal Injection Medical Research?, DOCTOR’S TABLET BLOG (May 6, 2014),
http://blogs.einstein.yu.edu/is-execution-by-lethal-injection-medical-research/.
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definitions to apply to experimental executions. However, states are
conducting experimental executions without considering the ethical and
regulatory framework that has been developed for biomedical research
and the resulting legal safeguards. In particular, research with captive
and vulnerable populations requires adherence to the ethical principles
of respect for autonomy, non-maleficence, and justice. Viewing lethal
injection executions through this lens can help ensure that states have a
solid scientific basis and are neither excessively risky nor disrespectful
of inmates on death row.
Additionally, the ethical and regulatory framework governing
biomedical research can complement an Eighth Amendment analysis. A
research ethics framework offers a way to adjudicate amongst competing
risk standards for determining how to apply the prohibition on cruel and
unusual punishment to risks posed by executions by lethal injection. The
most recent lethal injection case to be heard by the Supreme Court, Baze
v. Rees, 33 did not provide clear guidance on the appropriate standard for
weighing risks. 34 The Supreme Court has now granted certiorari to
review Oklahoma’s execution protocol in the case of Glossip v. Gross, 35
and is likely to address the changes in execution drugs being used since
its ruling in Baze. 36 Importantly, the plurality opinion in Baze indicated
that a lethal injection protocol would violate the Eighth Amendment if it
involves a “substantial risk of serious harm” or an “objectively
intolerable risk of harm,” and there are alternative execution methods
that effectively address this risk. 37 When faced with examples of
problematic executions, the Court opined that “an isolated mishap,” or
an “accident, with no suggestion of malevolence” would not be enough
to sustain a challenge based on the Eighth Amendment. 38 Yet, states are
increasingly engaged in experimentation that disregards many potential
risks and the considerable uncertainty as to whether procedures will
work as planned. Given the growing number of examples of executions
gone wrong, it is difficult to believe that these failures are merely a
series of accidents. Rather, the problem is systemic and foreseeable.
Poorly regulated and haphazard experimentation on inmates predictably
leads to bad outcomes.
33. 553 U.S. 35 (2008).
34. Id. at 52.
35. Warner v. Gross, No. CIV–14–0665–F, 2014 WL 7671680 (W.D. Okla. Dec. 22, 2014), aff’d,
776 F.3d 721 (10th Cir. 2015), cert. granted, No. 14-7955, 2015 WL 302647 (U.S. Jan. 23, 2015).
36. Id.
37. Baze, 553 U.S. at 50, 52.
38. Id. at 50.
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To put this argument in context, it is important to understand that the
examples of botched executions described above and in the media are
attributable to the recent, rapid pace of change in executions by lethal
injection across the country. These developments give new reason to be
concerned about the uncertain and troubling risks of excruciating pain
and suffering prior to death. The lethal injection approach traditionally
used by states was a three-drug protocol, which led to a risk that any
pain and suffering experienced by the inmate would be masked by the
use of a paralytic agent. 39 Now, states are using new drugs, in new
combinations and doses, and making such quick changes to their
protocols that it is increasingly difficult to predict what the outcome of a
given execution might be. 40 Moreover, many inmates were or could be
subjects of this experimentation: thirty-nine inmates were executed in
2013, thirty-five were executed in 2014, and over 3,000 inmates remain
on death row. 41
For the sake of clarity, a caveat may be in order. This Article is not
advocating for or against the death penalty or executions by lethal
injection. Rather, the goal of this Article is to ensure that—given that
execution by lethal injection persists in many states—it is properly
regulated and borrows from well-thought-out standards developed in
bio-medical research that address the concerns that arise when the
interests of experimenters, their subjects, and the rest of society diverge,
and the subjects of these experiments face uncertain risks of bodily
harm.
This argument is developed in four parts. In Part I of the Article, I
describe the history of research ethics and regulation, with extra
attention to research conducted on prisoners. Understanding the troubled
history of research on prisoners helps make sense of the existing ethical
and regulatory protections governing research on prisoners. In Part II, I
explain how current lethal injection protocols came into being. I then
argue in Part III that the best way to understand lethal injection
experimentation is through the lens of evidence-based medicine. I
contend that executions by lethal injection involve biomedical research

39. Denno, supra note 27, at 1333–34.
40. Id. at 1358 chart 3.
41. Death Row Inmates by State as of October 1, 2014, DEATH PENALTY INFO. CTR.,
http://www.deathpenaltyinfo.org/death-row-inmates-state-and-size-death-row-year (last visited Jan.
PENALTY
INFO.
CTR.,
23,
2014);
Execution
List
2013,
DEATH
http://www.deathpenaltyinfo.org/execution-list-2013 (last visited Feb. 9, 2015). Thirty-five people
were executed in 2014. Execution List 2014, DEATH PENALTY INFO. CTR.,
http://www.deathpenaltyinfo.org/execution-list-2014 (last visited Feb. 9, 2015).
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that is poorly designed and not based in evidence. Part IV argues that
states should therefore either rely on existing evidence or conduct more
systematic research, and identifies the regulations that should be applied
to lethal injection. In this section, I also take note of the gaps in the
regulation of poorly conducted research, and determine which
regulations are drafted broadly enough to apply to experimental
executions. I conclude by briefly addressing alternative approaches to
executions and the challenges they involve, and considering the
implications of this analysis for future scholarly work on both execution
by lethal injection and biomedical research regulation and ethics.
I.

A BRIEF HISTORY OF RESEARCH ON PRISONERS

This section first provides historical background for the development
of principles and regulations that govern the conduct of biomedical
research in the United States, with a particular focus on research on
prisoners. Next, I address a potential objection to the line of argument
contained in this Article: Why is it appropriate to apply the principles
and protections governing biomedical research with human subjects to
the context of capital punishment? I argue that the contexts of research
and capital punishment are not as different as they might initially seem
to be, and that there are important lessons learned from the history of
research on prisoners that should not be forgotten. The mere fact that an
inmate is sentenced to death should not suspend the standard protections
to which all of us are entitled.
A.

History of Research Ethics and Regulation

The ethics and regulation of clinical research have famously been
described as “born in scandal and reared in protectionism.” 42 This quote
is a particularly apt characterization of the history of research on
prisoners. In his book, Acres of Skin, Allen Hornblum chronicles several
studies in which prisoners were used as research subjects without
concern for their welfare. 43 Many of these early experiments
demonstrated a willingness to expose inmates to very high risks of injury
or death, and also had an insufficient scientific basis for pursuing such
an investigation in the first place. 44 In fact, in the Nuremberg trials, Nazi
42. Carol Levine, Has AIDS Changed the Ethics of Human Subjects Research?, 16 L. MED. &
HEALTH CARE 167, 167 (1988).
43. See generally ALLEN M. HORNBLUM, ACRES OF SKIN: HUMAN EXPERIMENTS AT
HOLMESBURG PRISON (1998).
44. Id. at xviii–xx.
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physicians who had conducted unconscionable experimentation on
victims of the Holocaust tried to defend their actions by arguing that
U.S. physicians had long conducted similarly disturbing experiments on
prisoners. 45 In describing what motivated these uses of prisoners in
research, some scholars argue that “a social consensus that certain
subgroups are unequal can seem to justify experimentation that
otherwise might not occur.” 46
One example cited at Nuremberg was a poorly run cholera trial
conducted by an American physician in the Philippines in 1906. 47 At the
time, the Philippines was an American territory, and Dr. Richard Strong
was a laboratory director at the Philippine Bureau of Science. Dr. Strong
conducted potentially fatal experiments on death row inmates in Manila
without their consent. 48 Although a U.S. government report concluded
that the deaths occurred because these inmates were mistakenly injected
with plague serum instead of cholera serum, others believed that the
inmates were deliberately injected with plague to try to induce an
immune response. 49 Dr. Strong subsequently conducted experiments on
prisoners by withholding adequate nutrition and thereby causing them to
develop beriberi, a serious disease that could cause paralysis and heart
failure. 50 These experiments also resulted in several deaths. 51 Similar
research on nutrition occurred within the United States. Around this
same time, the Louisiana Board of Health put black prisoners on a strict
diet of molasses for five weeks to learn whether sulfuric acid (used in
making molasses) was harmful. 52
Experimentation on prisoners became much more prevalent during
World War II, when physicians struggled to find treatments for the
diseases that were afflicting American soldiers. 53 The Terre Haute
Experiments, which were conducted between 1943 and 1944, 54 were
designed to develop a technique that would consistently infect prisoners
45. Id. at xvi.
46. Valerie H. Bonham & Jonathan D. Moreno, Research with Captive Populations: Prisoners,
Students, and Soldiers, in THE OXFORD TEXTBOOK OF CLINICAL RESEARCH ETHICS 461, 463
(Ezekiel J. Emanuel et al. eds., 2008).
47. HORNBLUM, supra note 43, at 76.
48. Id.
49. Id.
50. Id.
51. Id.
52. Id. at 76–77.
53. Id. at 80–83.
54. PRESIDENTIAL COMM’N FOR THE STUDY OF BIOETHICAL ISSUES, “ETHICALLY IMPOSSIBLE”
STD RESEARCH IN GUATEMALA FROM 1946 TO 1948, at 13 (2013).
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with gonorrhea by applying bacteria to the prisoners’ genitals. 55 These
experiments were the precursor to even more egregious experiments
later conducted in Guatemala, for which the U.S. government has
formally apologized. 56
Some experiments even involved prisoners on death row. The New
York Times wrote about a case where a prisoner was pardoned from a
death sentence as a result of participation in a risky medical
experiment. 57 One physician wrote a letter to the New York Times
criticizing the lack of a scientific basis for the study and the risks
involved. 58 Human experimentation with prisoners was commonplace by
the 1950s and 60s. 59 By the 1970s, approximately eighty-five percent of
all phase I trials (or studies conducted with the primary objective of
learning about the safety of the experimental intervention, and not to
benefit the subjects of the research) were conducted on prisoners. 60
In 1962, one of the first efforts to examine the ethics of research on
prisoners took place at a conference held at Boston University. 61 The
conference attendees, among whom were both researchers and prison
officials, felt that research on prisoners was not likely to be of concern
for the general public, stating: “When the public hears that inmates are
[participating in a seemingly very hazardous study], they rationalize
‘Well, I wouldn’t do it, but it’s all right with prisoners.’” 62 Many also
thought that the public would be more willing than researchers to have
prisoners be exposed to high risks. 63
Given this history, it is surprising to learn that the principles
governing ethically responsible research were established prior to these
scandals, in the early twentieth century. 64 The physician William Osler
55. Id. at 21 (the presumption was that prisoners would volunteer in order to help the war effort).
56. Donald G. McNeil, Jr., Syphilis Experiment Is Revealed, Prompting U.S. Apology to
Guatemala, N.Y. TIMES, Oct. 1, 2010, at A1.
57. Id. at 87–88.
58. Id. at 89.
59. HORNBLUM, supra note 43, at xviii.
60. Proposed Rules, 42 Fed. Reg. 3085 (proposed Jan. 14, 1977) (to be codified at 45 C.F.R. pt.
46); NAT’L COMM’N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL & BEHAVIORAL
RESEARCH, REPORTS & RECOMMENDATIONS: RESEARCH INVOLVING PRISONERS 47 (1976)
[hereinafter RESEARCH INVOLVING PRISONERS].
61. Bonham & Moreno, supra note 46, at 463.
62. Id. at 463.
63. See id.
64. See, e.g., SUSAN E. LEDERER, SUBJECTED TO SCIENCE: HUMAN EXPERIMENTATION IN
AMERICA BEFORE THE SECOND WORLD WAR 22 (1995) (citing prominent physician William Osler
for his criticism of a study that failed to obtain informed consent in 1898); Paul J. Weindling, The
Nazi Medical Experiments, in THE OXFORD TEXTBOOK OF CLINICAL RESEARCH ETHICS 18, 19
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argued in 1907 that interventions could be tested in humans only after
animal testing had occurred, consent was obtained from the research
subjects, and direct benefit to the individual subjects was likely. 65
Eventually, research on prisoners that violated these and other ethical
principles led to controversy. Newspaper editorials questioned whether
prisoners were coerced into research participation. 66 Congressional
hearings were held in 1973, in which concerns about “exploitation,
secrecy, danger, and the impossibility of obtaining informed consent”
were cited as reasons to prohibit research on prisoners. 67 As a result of
these hearings, a bill was introduced to establish the National
Commission for the Protection of Human Subjects of Biomedical and
Behavioral Research. 68
In the late 1970s, Congress gave the Commission the task to “identify
the basic ethical principles that should underlie the conduct of
biomedical and behavioral research involving human subjects and to
develop guidelines to assure that such research is conducted in
accordance with those principles.” 69 The Commission authored the
Belmont Report, one of the most influential documents in research ethics
to date. In this report, the Commission addressed “the boundaries
between biomedical and behavioral research and the accepted and
routine practice of medicine.” 70 The resulting discussion is particularly
instructive here.
The Commission recognized that it is important to distinguish
between biomedical research and clinical practice, but that it can be
challenging to draw this distinction given that “notable departures from
standard practice are often called ‘experimental’ when the terms

(Ezekiel J. Emanuel et al. eds., 2008) (citing the German Reich Circular on Human Experimentation
from 1931, which required advance consent to research and limits on research with children).
65. Arthur O. Anderson & James R. Swearengen, Scientific and Ethical Importance of Animal
Models in Biodefense Research, in BIODEFENSE: RESEARCH METHODOLOGY AND ANIMAL MODELS
25, 27 (James R. Swearengen ed., 2012) (citing William Osler, The Historical Development and
Relative Value of Laboratory and Clinical Methods in Diagnosis. The Evolution of the Idea of
Experiment in Medicine, in TRANSACTIONS OF THE CONGRESS OF AMERICAN PHYSICIANS AND
SURGEONS
1–8
(1907)),
available
at
http://artandersonmd.com/
2006.animal.models.biodefense.research.pdf).
66. Id. at 3.
67. RESEARCH INVOLVING PRISONERS, supra note 60, at 3.
68. Id. at 3–4.
69. NAT’L COMM’N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL & BEHAVIORAL
RESEARCH, THE BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR THE PROTECTION
OF HUMAN SUBJECTS OF RESEARCH 1 (1979) [hereinafter THE BELMONT REPORT].
70. Id.
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‘experimental’ and ‘research’ are not carefully defined.”71 The
Commission argued that the distinction is largely based on the intent
behind the activity. Essentially, medical practice is about helping
individual patients, whereas research is about learning from individuals
to develop knowledge that can be applied to other, future patients. 72 Any
departure from standard practice does not necessarily constitute
research, however; nor does “the fact that a procedure is ‘experimental,’
in the sense of new, untested or different” turn it into research. 73 Yet, the
Commission cautioned, experimental procedures should “be made the
object of formal research at an early stage in order to determine whether
they are safe and effective.” 74
After discussing the boundary between research and practice, the
Commission turned its attention to the general principles that should
govern the conduct of research. It determined that three core ethical
principles should apply to research: respect for persons, beneficence, and
justice. 75 Respect for persons requires recognizing that individuals
should be treated as autonomous agents, and individuals who are not
able to make their own decisions should be protected from risk.
Respecting autonomous individuals serves at least two functions. The
value of treating individuals as autonomous agents is not just to show
them respect by letting them do as they choose (within certain
constraints, of course), but also because individuals are often bestpositioned to make decisions that protect their own interests. The
Commission specifically applied this principle to the conduct of research
involving prisoners as follows:
In most cases of research involving human subjects, respect for
persons demands that subjects enter into the research voluntarily
and with adequate information. In some situations, however,
application of the principle is not obvious. The involvement of
prisoners as subjects of research provides an instructive
example. On the one hand, it would seem that the principle of
71. Id. at 3.
72. Id. More specifically, the National Commission contended that medical practice refers to
“interventions that are designed solely to enhance the well-being of an individual patient or client
and that have a reasonable expectation of success. The purpose . . . is to provide diagnosis,
preventative treatment, or therapy to particular individuals.” Id. at 3–4. By contrast, research is an
“activity designed to test an hypothesis, permit conclusions to be drawn, and thereby to develop or
contribute to generalizable knowledge . . . . Research is usually described in a formal protocol that
sets forth an objective and a set of procedures designed to reach that objective.” Id. at 4.
73. Id. at 4.
74. Id.
75. Id.
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respect for persons requires that prisoners not be deprived of the
opportunity to volunteer for research. On the other hand, under
prison conditions they may be subtly coerced or unduly
influenced to engage in research activities for which they would
not otherwise volunteer. Respect for persons would then dictate
that prisoners be protected. Whether to allow prisoners to
“volunteer” or to “protect” them presents a dilemma. Respecting
persons, in most hard cases, is often a matter of balancing
competing claims urged by the principle of respect itself. 76
The Commission determined that, in research, the principle of respect
for persons requires asking potential research subjects for their informed
and voluntary consent to participate in the research, provided that they
are capable of making their own decisions. They also specified that this
requires informing potential research subjects about “the research
procedure, their purposes, risks and anticipated benefits, alternative
procedures (where therapy is involved), and a statement offering the
subject the opportunity to ask questions and to withdraw at any time
from the research.” 77
The second principle the Commission thought should be applied to
research with human subjects is the principle of beneficence. Although it
described this principle as requiring that researchers do no harm,
maximize possible benefits, and minimize potential harms, 78 it is not
straightforward to apply the principle of beneficence to research.
Because research involves testing interventions with uncertain risks and
benefits, and research procedures are sometimes needed to understand
how these interventions are working in the body, it is difficult to
conceive of research that would not do any harm. Moreover, the
requirement to maximize benefits could be overly demanding and come
into conflict with the primary duty that researchers have to develop
generalizable knowledge. Therefore, scholars now understand the
obligation of beneficence to require that harms are minimized in
research, and that unnecessary harms are not imposed on research
subjects. 79 This is also consistent with the way the Commission applied
the principle of beneficence in the Belmont Report—it notes that
beneficence requires the systematic assessment of risks and benefits, and
ensuring that “risks should be reduced to those necessary to attain the
76. Id. at 5.
77. Id. at 7.
78. Id. at 5.
79. Steven Joffe & Franklin G. Miller, Bench to Bedside: Mapping the Moral Terrain of Clinical
Research, HASTINGS CTR. REP., Mar.–Apr. 2008, at 30, 36.
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research objective.” 80
The final principle the Commission argued should apply to research is
justice. In research, justice requires the fair and equal distribution of the
burdens and benefits of research. In particular, it explained that “the
principle of justice gives rise to moral requirements that there be fair
procedures and outcomes in the selection of research subjects.” 81 It was
particularly concerned that only “undesirable” persons might be selected
for risky research. 82
In a subsequent report, the Commission was also charged with
specifically addressing the participation of prisoners in biomedical and
behavioral research. 83 The Commission noted that, in general, prisoners
did not participate in biomedical research outside the United States, and
attributed this to international concern about experiments conducted by
the Nazis on holocaust victims. 84 The Commission raised two important
ethical concerns about prisoner participation in research: exploitation
and autonomy. The Commission specifically was concerned that (1)
prisoners were being exploited by being exposed to risky research, and
(2) prisoners may not be able to give voluntary informed consent to
research participation because they live in a coercive environment. 85 The
Commission made a strong statement about the importance of protecting
prisoners from exploitation:
It has become evident to the Commission that, although
prisoners who participate in research affirm that they do so
freely, the conditions of social and economic deprivation in
which they live compromise their freedom. The Commission
believes, therefore, that the appropriate expression of respect
consists in protection from exploitation. Hence it calls for
certain safeguards intended to reduce the elements of constraint
under which prisoners give consent and suggests that certain
kinds of research would not be permitted where such safeguards
cannot be assured. 86
The Commission’s report led to strict regulations governing research
on prisoners. Various federal agencies have promulgated regulations
greatly influenced by the Commission’s report. For example,
80.
81.
82.
83.
84.
85.
86.

THE BELMONT REPORT, supra note 69, at 10.
Id. at 11.
Id.
See RESEARCH INVOLVING PRISONERS, supra note 60, at vii–ix.
Id. at 2–3.
Id. at 5.
Id. at 6–7.
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Department of Health and Human Services (DHHS) regulations provide
that research on prisoners should not take place unless the research is
likely to have some benefit for prisoners as a group or for individual
prisoners enrolled in the research. 87 There are also regulations
promulgated by the Federal Bureau of Prisons that stem from the
Commission’s work; these regulations govern research involving
prisoners that is conducted within the Federal Bureau of Prisons. These
regulations are slightly different from the DHHS regulations. 88 Finally,
the Food and Drug Administration (FDA) attempted to enact a set of
prisoner regulations similar to those adopted by the DHHS in 1978. 89
However, presumably out of concern that they would not have access to
potentially beneficial research, prisoners in the Michigan State
Penitentiary alleged that these proposed regulations violated the Equal
Protection and Due Process Clauses of the Fifth Amendment. 90 The
existing FDA regulations that cover human subjects research in general
do, however, have at least one protection that would apply to research
with prisoners. Current FDA regulations require that Institutional
Review Boards (IRBs), which regularly review research involving a
particular vulnerable group (such as prisoners), consider including
someone on the board who has knowledge and expertise in working with
members of the group. 91
Many states have also passed laws of varying degrees of
restrictiveness that limit or even prohibit the conduct of research on
prisoners within state departments of corrections. 92 This protectionist
response was viewed by many as an overcorrection, which led to
prisoners being denied the benefits associated with some types of
research and insufficient investigation of the kinds of illnesses that
87. See 45 C.F.R. § 46 subpart C (2014). The exceptions provided in this subpart are discussed at
greater length in Part III.C, infra.
88. See 28 C.F.R. § 512 (2014). Note that unlike the DHHS regulations, which only apply to
federally funded research, the Bureau of Prisons regulations appear to apply to any research
conducted within the Bureau. Id. § 512.10. Furthermore, although some research conducted by
employees of the Bureau is exempt from some regulations, no research is exempt from part 512,
which is the relevant part for my analysis. Id.
89. 45 Fed. Reg. 19,417, 19,418 (May 5, 1978) (to be codified at 21 C.F.R. pt. 50 Subpart C)
(referring to subpart C of the DHHS regulations, but going beyond these regulations by including
statements such as: “no prisoner may serve as a placebo control”).
90. See Sharona Hoffman, Beneficial and Unusual Punishment: An Argument in Support of
Prisoner Participation in Clinical Trials, 33 IND. L. REV. 475, 491–92 (2000).
91. 21 C.F.R. § 56.107(a) (2014); id. § 56.111. Note, however, that the FDA revoked these
regulations in 1997 for being “obsolete or no longer relevant to public health goals.” 62 Fed. Reg.
39,439 (July 23, 1997).
92. Shah, supra note 32, at 1146 app. 1.
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disproportionately affect prisoners. In fact, an Institute of Medicine
committee issued a report in 2006, in which it acknowledged “that
access to research may be critical to improve the health of prisoners and
the conditions in which they live.” 93 The report argued that more
research calculated to benefit individual inmates and prisoners as a
group should be permitted. 94 Despite this regulatory response to abuses
and scandals of the past, public distrust of biomedical research persists,95
particularly among African-Americans. 96 This distrust may stem from
historical scandals in research involving African-Americans, and may
also incorporate a more general lack of trust based on the legacy of
discrimination against African-Americans in the U.S. 97
In sum, the history of research involving prisoners in the United
States led to the recognition that the principles of respecting autonomy,
beneficence, justice, and avoiding exploitation should guide the conduct
of research with human subjects. This history also led to the
development of strict research regulations that, as I will argue below,
apply to some of the current experimentation on lethal injection. First, I
will head off an important potential objection to this line of inquiry—
should ethical principles and legal protections developed for research
subjects be applied to the domain of capital punishment?
B.

Should Research Protections Apply to Capital Punishment?
Biomedical research involves risks of bodily harm and a divergence

93. COMM’N ON ETHICAL CONSIDERATION FOR REVISIONS TO DHHS REGULATIONS FOR PROT.
PRISONERS INVOLVED IN RESEARCH, ETHICAL CONSIDERATIONS FOR RESEARCH INVOLVING
PRISONERS 4 (Lawrence O. Gostin et al. eds., 2007) [hereinafter ETHICAL CONSIDERATIONS]. The
Institute of Medicine is an arm of the National Academy of Sciences that regularly convenes
committees to issue influential reports, often at the behest of Congress or federal agencies. See
About the IOM, INST. OF MED., http://iom.edu/About-IOM.aspx (last visited Nov. 4, 2013).
94. ETHICAL CONSIDERATIONS, supra note 93, at 4.
95. Raegan W. Durant et al., Different Types of Distrust in Clinical Research Among Whites and
African Americans, 103 J. NAT’L. MED. ASS’N. 123, 123 (2011).
96. See, e.g., Joel B. Braunstein et al., Race, Medical Research Distrust, Perceived Harm, and
Willingness to Participate in Cardiovascular Prevention Trials, 87 MED. 1, 5 (2008); Giselle
Corbie-Smith et al., Distrust, Race, and Research, 162 ARCHIVES OF INTERNAL MED. 2458, 2459
(2002); Vickie L. Shavers, Charles F. Lynch, & Leon F. Burmeister, Knowledge of the Tuskegee
Study and its Impact on the Willingness to Participate in Medical Research Studies, 92 J. NAT’L
MED. ASS’N. 563, 567 (2000). I have noted elsewhere that lethal injection research has the potential
to harm biomedical research, given that distrust of research is particularly high among AfricanAmericans, and that African-Americans are overrepresented on death row. Shah, supra note 32, at
1146 n.232.
97. Jill A. Fisher & Corey A. Kalbaugh, Challenging Assumptions About U.S. Minority
Participation in U.S. Clinical Research, 101 AM. J. PUB. HEALTH 2217, 2218–19 (2011).
OF
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of interests between those conducting research and those subjected to it.
It is particularly vulnerable to exploitation and abuse. Research is an
activity that involves trying interventions that may or may not work to
produce scientific knowledge that can benefit others in society, and may
pose risks of bodily harm for the individual subjects of the research. The
interests of the researcher and the sponsors of the research are to find out
something that was not previously known, and to receive benefits from
the production of that knowledge. These benefits may include prestige,
status, career advancement, satisfaction of curiosity, and money. By
contrast, research subjects may benefit from the research intervention,
but may also face significant risk. They are also unlikely to benefit from
the production of the knowledge in a significant way. Safeguards for
research have therefore been developed that help protect research
subjects and ensure that valuable research can proceed and new
knowledge can be generated.
The current approaches to lethal injection executions involve
exposing inmates to new and uncertain risks of bodily harm from
untested drugs and drug combinations. The interests of prison officials
are to find methods of lethal injection that are effective, appear to have a
low risk of causing significant pain and suffering, and are based on using
drugs they can access and procedures they can implement. There is great
potential for abuse and exploitation of prisoners because prison officials’
interests differ so dramatically from those of inmates. There is
considerable uncertainty about whether some of these drugs will cause
death without also causing excessive and torturous pain. Additionally,
executions are justified on the basis that they further societal goals of
deterrence and retribution. The potential for abuse suggests that the
principles and protections developed for biomedical research could be
very helpful in regulating executions by lethal injection.
Some might still question whether a research ethics framework is the
right approach to address worries about execution methods for several
reasons. First, perhaps executions should not be thought of as “medical”
in any respect. Second, the historical examples of research on prisoners
may differ in important respects from modern day executions by lethal
injection. Third, one might argue that capital punishment should be
judged on the basis of considerations specific to the criminal justice
system (such as whether the approach to executions furthers its goals of
deterrence and retribution), rather than the “subject protection”
framework that applies to research. Perhaps the research ethics
framework assumes a more robust conception of the interests and rights
of subjects than should be applied to capital punishment. Finally, maybe
death is different, and people who are already sentenced to death should
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not receive the same protections that others would. 98
Some have argued that lethal injections should be considered outside
of the practice of medicine altogether, and some states indicate in their
statutory codes that lethal injection does not constitute the practice of
medicine. 99 However, for the purposes of this analysis, lethal injections
do not have to be considered part of the practice of medicine. My
argument is that lethal injection executions involve a type of biomedical
research—something that is also outside the practice of medicine.100
Additionally, Mark Heath argues that some components of lethal
injection clearly use medical procedures for medical purposes. The
administration of drugs that paralyze the inmate or that have the sole
effect of causing death do not have clear medical purposes. But Heath
argues that “[a]dministration of general anesthesia, including the
induction, maintenance, and continued assessment of anesthetic depth, is
done to prevent severe pain; it is a therapeutic procedure and a medical
procedure.” 101 The use of anesthesia is necessary for all current lethal
injection protocols to avoid an unconstitutionally high risk of pain. This
suggests that lethal injections in the United States have a medical
component to them that cannot be removed.
It is true that there are some important differences between the history
of research on prisoners and current experimentation in lethal injection
executions that may support differential treatment. First, execution
research on inmates, unlike most research and most of the historical
research on prisoners, enrolls individuals who are going to die shortly.
This can be compared, however, to some examples of research on
individuals who suffer from terminal illnesses 102 or who will likely die
98. Note that the Supreme Court has explained that the fact that “the penalty of death is different
in kind from any other punishment imposed under our system of criminal justice” is a justification
for heightened protections, and not a justification for less scrutiny. Gregg v. Georgia, 428 U.S. 153,
188 (1976).
99. See, e.g., Amended Order Granting Plaintiff’s Request for Declaratory Relief and Denying
Defendant’s Motion to Dismiss, N.C. Dep’t of Corr. v. N.C. Med. Bd., No. 07-CV-003574 (N.C.
Oct. 1, 2007); Complaint, N.C. Dep’t of Corr. v. N.C. Med. Bd., No. 07-CV-003574 (N.C. March 6,
2007); Deborah W. Denno, The Lethal Injection Quandary: How Medicine Has Dismantled the
Death Penalty, 76 FORDHAM L. REV. 49, 89 (2007) (explaining that eight states have statutes
expressly indicating that lethal injection executions do not constitute the practice of medicine);
William L. Lanier & Keith H. Burge, Physician Involvement in Capital Punishment: Simplifying a
Complex Calculus, 82 MAYO CLINIC PROC. 1043, 1046 (2007).
100. Paul Litton & Franklin G. Miller, What Physician-Investigators Owe Patients Who
Participate in Research, 304 J. AM. MED. ASS’N 1491, 1491 (2010).
101. Mark J. Heath, Revisiting Physician Involvement in Capital Punishment: Medical and
Nonmedical Aspects of Lethal Injection, 83 MAYO CLINIC PROC. 115, 116 (2008).
102. Erika Kleiderman et al., Recruiting Terminally Ill Patients into Non-Therapeutic Oncology
Studies: Views of Health Professionals, 13 BMC MED. ETHICS 33, 34 (2012).
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imminently. 103 In these categories of research, although long-term risks
may be discounted because subjects may not live long enough to
experience these consequences, the ethical issues regarding the treatment
of research subjects are still taken seriously. 104 Similarly, there is no
reason to disregard the risk of significant pain and suffering that an
inmate will experience before being executed, simply because he will
most likely be dead soon after experiencing them. Depending on why we
think pain is a negative experience, however, there may be some reason
to discount the pain experienced at the very end of life. There are at least
two aspects of pain that make it bad—the actual experience of pain and
the memory of it. Because inmates being executed will not live to
remember their experience of pain, how bad it is for them to suffer at the
end of life may need to be discounted from how we might ordinarily
evaluate pain. On the other hand, studies conducted by psychologists
asking subjects to evaluate the quality of different individuals’ lives
suggest that negative experiences at the end of life color the evaluation
of the life as a whole significantly. 105 Somewhat counterintuitively, this
research implies that there may be extra reason to think that severe pain
at the end of life is bad. Thus, it is hard to establish conclusively whether
the negative aspects of pain are diminished or increased if pain is
experienced at the end of life. Perhaps the safest conclusion is that the
fact that an inmate who is executed will not live to remember the pain
may give some reason to discount the level of pain an inmate
experiences, but does not eliminate other reasons to care about the
experience of pain in an execution.
Second, lethal injection experimentation may also differ from most of
human subjects experimentation because it may be less motivated by
scientific curiosity and the desire to improve human health. Such
experimentation is presently motivated at least in part by political
considerations and drug embargos that stem from ethical concerns about
the death penalty. 106 For example, a Danish drug maker and some
American pharmaceutical companies have taken steps to prevent their
drugs from being supplied to states for use in executions. 107 Yet, at least
103. Kate Murphy, Killing a Patient to Save His Life, N. Y. TIMES (June 9, 2014),
http://www.nytimes.com/2014/06/10/health/a-chilling-medical-trial.html.
104. Kleiderman et al., supra note 102, at 36–38.
105. See DANIEL KAHNEMAN, THINKING FAST AND SLOW 387–88 (2011).
106. Josh Sanburn, The Hidden Hand Squeezing Texas’ Supply of Execution Drugs, TIME (Aug.
7, 2013), http://nation.time.com/2013/08/07/the-hidden-hand-squeezing-texas-supply-of-executiondrugs/.
107. Id.; see also Par Pharmaceutical Statement on Brevital® Sodium, PAR PHARMACEUTICALS
(May 27, 2014), http://pr.parpharm.com/phoenix.zhtml?c=81806&p=irol-newsArticle&ID=

08 - Shah - final.docx (Do Not Delete)

2015]

EXPERIMENTAL EXECUTION

4/13/2015 11:51 AM

167

some biomedical research is conducted because of political
considerations or moral concerns. Consider, for example, the increased
research by the states and private companies spurred by President
George W. Bush’s decision to severely restrict federal funding for
research on the use of embryonic stem cell lines. 108
A third objection to considering certain aspects of lethal injection
executions medical research is that execution and research serve
different goals. In the history of research on prisoners and other
vulnerable subjects, the aim was to test products that could benefit
others. By contrast, some might argue that the goal of lethal injection
experimentation is to successfully execute the particular inmate, or
perhaps to make future executions of inmates more effective and less
objectionable. If the goals of the two types of research are different, the
history of research on prisoners may not help us to understand current
experimentation on death row inmates.
This objection, however, does not rely on an accurate view of the
motivations of both stakeholders in research and those involved in
conducting executions. Researchers and sponsors of research can have
many different motivations. They may want to test a treatment on
particular patients hoping to help those patients, and still have interests
in whether the treatment is likely to be safe and effective for use in
future patients. 109 Researchers may also conduct research in order to
satisfy their curiosity, build their reputation, or make money. 110
Similarly, although prison officials may want to ensure that a particular
inmate is executed without incident, they may also be very interested in
finding a method of execution that they can use without raising concern
from activists, judges, and the general public. And those who support
executions do so for at least one of a few different reasons. They may
believe that executions have a deterrent effect and prevent future crime;
they may think that punishment and retribution are morally appropriate
for those who have committed crimes of a certain degree; or they may
think that an execution gives comfort or justice to the victims of a crime
and their families. 111 This suggests that the purposes behind capital
1935104 (“As a pharmaceutical company, Par’s mission is to help improve the quality of life. The
state of Indiana’s proposed use is contrary to our mission.”).
108. Eileen Burgin, Human Embryonic Stem Cell Research and Proposition 71: Reflections on
California’s Response to Federal Policy, 29 POL. & LIFE SCI. 73 (2010); Constance Holden, States,
Foundations Lead the Way After Bush Vetoes Stem Cell Bill, 313 SCI. 420 (2006).
109. Joffe & Miller, supra note 79, at 33.
110. David Korn, Conflicts of Interest in Biomedical Research, 284 J. AM. MED. ASS’N 2234,
2234 (2000).
111. Cass R. Sunstein & Adrian Vermeule, Is Capital Punishment Morally Required?: Acts,
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punishment, like the purposes behind research, may include a desire to
benefit society in some way. Thus, inmates on death row are not immune
from the possibility of exploitation for the benefit of society.
Some might object that there is no reason to apply extra protections
for research on lethal injection because these prisoners are already
sentenced to death. A more extreme view might be that any additional
suffering is what death row inmates deserve, based on the crimes that led
to a death sentence. 112 Although the Constitution has been interpreted to
permit the imposition of death sentences, it expressly forbids cruel and
unusual punishment. Thus, unless the Constitution is amended to
eliminate the cruel and unusual punishment clause of the Eighth
Amendment or the death penalty is determined to be unconstitutional
under evolving standards of decency, 113 we must evaluate methods of
execution to ensure that they are not cruel and unusual. As the U.S.
Supreme Court explained in In re Kemmler, 114 “[p]unishments are cruel
when they involve torture or a lingering death; but the punishment of
death is not cruel within the meaning of that word as used in the
constitution. It implies there is something inhuman and barbarous—
something more than the mere extinguishment of life.” 115 Austin Sarat
further argues that an important purpose is served by ensuring that the
death penalty is administered humanely:
Even as capital punishment seeks to do justice and/or satisfy the
public desire for vengeance, the state has countervailing
concerns. It must distinguish execution from the acts to which it
is a supposedly just response. The state must also find ways of
killing in a manner that does not allow the condemned to
become an object of pity, or to appropriate the status of the
victim. 116
Sarat goes on to note that, “[l]aw imposes on sovereignty the
requirement that no matter how heinous the crime or how reprehensible
the criminal, we not do death as death has been done by those we
Omissions, and Life-Life Tradeoffs, 58 STAN. L. REV. 703, 704–05 (2006).
112. See Matt McCarthy, What’s the Best Way to Execute Someone?, SLATE (Mar. 27, 2014,
11:44 PM), http://www.slate.com/articles/health_and_science/medical_examiner/2014/03/death_
penalty_drugs_lethal_injection_executions_are_so_bad_that_it_s_time.html.
113. Trop v. Dulles, 356 U.S. 86, 100–01 (1958).
114. 136 U.S. 436 (1890).
115. Id. at 447. Although Kemmler has been cited in subsequent Supreme Court cases as confined
to outlawing “barbarous” forms of punishment, the standards used by the Supreme Court today are
meant to be broader than this and to reflect “evolving standards of decency.” See Gregg v. Georgia,
428 U.S. 153, 173 (1976).
116. SARAT ET AL., supra note 28, at 5.
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punish . . . . We kill humanely, not out of concern for the condemned but
rather to vividly establish a hierarchy between the law-abiding and the
lawless.” 117 This suggests that there is reason to ensure the death penalty
is administered humanely whether or not one has any concern for the
welfare of the inmates being executed.
The research enterprise also depends on trust in the system, and to the
extent that the public is beginning to view executions as poorly
conducted research, public trust in research may be affected by lethal
injection executions. 118 Allowing death penalty research to proceed
unchecked and immune from regulatory scrutiny sets a precedent that
could erode confidence in research more generally, particularly as
questions about the experimental nature of executions are asked more
frequently. 119 It is also true that many historical scandals arose out of
research conducted on people who were considered disposable, or
unworthy of moral consideration, by mainstream society. 120
Finally, and perhaps most importantly, it is not clear why the
imposition of the death penalty should suspend all other legal
protections. As the Supreme Court explained in a case about FDA
review of lethal injection drugs, “The fact that the drugs involved in this
case are ultimately to be used in imposing the death penalty must not
lead this Court or other courts to import profound differences of opinion
over the meaning of the Eighth Amendment to the United States
Constitution into the domain of administrative law.” 121 The same logic
applies to the domain of research regulation.
In sum, there are enough similarities and common principles shared
between new death penalty protocols and more traditional biomedical
research that it is appropriate to evaluate them in similar ways. As I will
demonstrate below, insights from the domain of research ethics and
regulation can help to ensure that executions by lethal injection are not
excessively risky or disrespectful of inmates.
II.

HISTORICAL AND CURRENT DEVELOPMENTS IN
EXECUTION BY LETHAL INJECTION
Many articles have described the history of how the first lethal

117. Id. at 28.
118. See Alex J. London, A Non-Paternalistic Model of Research Ethics and Oversight:
Assessing the Benefits of Prospective Review, 40 J.L. MED. & ETHICS 930, 930 (2012).
119. See Kiefer, supra note 18.
120. See Bonham & Moreno, supra note 46, at 461–63.
121. Heckler v. Chaney, 470 U.S. 821, 838 (1985).
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injection protocol was developed, 122 so I will discuss the history only
briefly and then turn to more recent changes to and problems with
executions by lethal injection.
A.

Brief History of Execution by Lethal Injection

The first time lethal injection was considered as a possible method of
execution was in the late nineteenth century, when a New York state
commission rejected it as an option based on the concern that the public
would associate the practice of medicine with causing death.123 The
U.K.’s Royal Commission on Capital Punishment conducted a study in
the 1950s to evaluate the relative merits of execution by lethal injection
versus execution by hanging, and identified several problems that led the
members of the commission not to recommend lethal injection as a
possible execution method. 124 The Royal Commission was particularly
concerned about problems associated with individuals with veins that
were difficult to access and the need for someone on the execution team
to have complex medical skills. 125 The British Association of
Anaesthetists explained to the Royal Commission that lethal injection
was impractical because of concerns that: (1) it would be impossible to
administer intravenous injections to people with “certain physical
abnormalities,” (2) it is difficult to inject people against their will, and
(3) medical skills and training would be needed, but members of the
medical profession would not be willing to provide their assistance. 126
The Commission did believe, however, that lethal injection might be a
more humane and painless method than other methods, and suggested
that gradual adoption of lethal injection in a systematic manner, coupled
with the state taking “all possible means to ensure that the act is

122. Denno, supra note 99, at 64–65; see generally Shah, supra note 32.
123. Denno, supra note 99, at 64.
124. ROYAL COMM’N ON CAPITAL PUNISHMENT, 1949–1953, REPORT 261 (1953) (U.K.) (“Our
own collective verdict must be a negative one: we cannot agree to recommend that in the present
circumstances lethal injection should be substituted for hanging as the method of judicial execution
in this country. If we could have been satisfied that executions could be carried out in this way
quickly, painlessly and decently in all cases, we should have recommended its adoption
unanimously. But we are bound to conclude from our expert evidence that there is not at present a
reasonable certainty of this. We do, however, recommend, unanimously and emphatically, that the
question should be periodically examined, especially in the light of progress made in the science of
anaesthetics, with a view to a change of system being proposed to Parliament as soon as it can be
shown that there are no longer any grounds for the doubts that now deter us from recommending
it.”).
125. Id. at 257–59.
126. See id. at 258–59.
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performed with dignity, solemnity, speed, and certainty,” might make
sense in the future. 127
Notwithstanding these earlier qualms about execution with lethal
injection, along with the views of its own state senators that there was a
need for more research before lethal injection should be adopted, 128 the
State of Oklahoma adopted a lethal injection protocol in 1977. 129 Jay
Chapman, the state’s medical examiner, was asked by a state legislator
to develop a lethal injection protocol. Dr. Chapman initially replied that
he “was an expert in dead bodies but not an expert in getting them that
way.” 130 Yet, Dr. Chapman first proposed that lethal injection could
involve an “ultra-short-acting barbiturate in combination with a chemical
paralytic.” 131 In 1981, Chapman modified his initial proposal protocol to
add a third drug, potassium chloride, thereby developing the three-drug
protocol that became the standard for execution in the United States until
recently. 132
B.

More Recent Developments in Executions

By 2008, all of the thirty-eight jurisdictions 133 that permitted
execution by lethal injection used the protocol Chapman developed and
administered a sequence of three drugs intravenously. 134 The first drug
was a dose of sodium thiopental that was given in a lethal dose. But this
dose takes a relatively long time to result in death, and the drug was not
expected to cause death before the rest of the drugs take effect. Rather, it
was administered for its anesthetic effects. The second chemical was
pancuronium bromide, a neuromuscular blocking agent that paralyzes
the inmate. This chemical was used to further the state’s interest in
dignity by making the dying process appear serene. 135 However,

127. Id. at 259.
128. John Greiner, Drug Execution Plan Suffers Senate Setback, DAILY OKLAHOMAN, Feb. 16,
1977, at 16.
129. OKLA. DEP’T OF CORR., NO. P-090901, OKLAHOMA POLICY STATEMENT, PROCEDURES FOR
CARRYING OUT THE DEATH SENTENCE (1978) (citing OKLA. DEP’T OF CORR., NO. P-090900,
OKLAHOMA POLICY STATEMENT, PROCEDURES FOR CARRYING OUT THE DEATH SENTENCE (1977)).
130. Denno, supra note 99, at 65–66.
131. Id. at 66–67.
132. Id. at 74.
133. TRACY L. SNELL, U.S. DEP’T OF JUSTICE, BUREAU OF JUSTICE STATISTICS, CAPITAL
PUNISHMENT, 2008—STATISTICAL TABLES, at 5 tbl.2 (2009), available at http://www.bjs.gov/
content/pub/pdf/cp08st.pdf.
134. Shah, supra note 32, at 1105.
135. Baze v. Rees, 553 U.S. 35, 49 (2008).
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pancuronium bromide also makes problems in the administration of the
first drug difficult, if not impossible, for witnesses to detect. 136 Finally,
potassium chloride was administered to cause death by cardiac arrest.137
If everything went according to plan, the first drug anesthetized the
inmate from pain, the second drug prevented the inmate’s spasms or
death throes from disturbing the audience, and the third drug caused
death quickly. If the anesthetic was not administered correctly, however,
all parties now agree that the inmate would experience excruciating
suffering before death. 138
Some examples of executions that seemed to go poorly raised concern
about the three-drug protocol. In Florida, Governor Jeb Bush
temporarily halted executions in the state after Angel Diaz’s botched
execution in December of 2006. 139 An autopsy revealed that the lethal
injection administered to Mr. Diaz was not inserted into his veins, but
rather into the soft tissue of his arms. 140 He sustained chemical blisters
of a foot in length on both of his arms, and because the effect of the
anesthesia administered was likely diluted, he seemed to have
experienced agonizing pain. 141
In California, a court reviewing lethal injection evidence was troubled
by the fact that “anomalies in six execution logs raise substantial
questions as to whether certain inmates may have been conscious”
during the procedure. 142 These outcomes were concerning because when
an inmate is not sufficiently anesthetized before lethal drugs are
administered, “the inmate may suffer excruciating suffocation.”143 Based
on this and other evidence, executions in California were stayed by a
district court judge. 144 Similar problems arose all over the country. 145 In
136. Denno, supra note 99, at 55–56.
137. Ty Alper, Lethal Incompetence: Lethal Injection Litigation Is Exposing More Than
Torturous Executions, THE CHAMPION, Sept.–Oct. 2006, at 41.
138. Baze, 553 U.S. at 53 (“It is uncontested that, failing a proper dose of sodium thiopental that
would render the prisoner unconscious, there is a substantial, constitutionally unacceptable risk of
suffocation from the administration of pancuronium bromide and pain from the injection of
potassium chloride.”).
139. Ben Crair, Photos from a Botched Lethal Injection, NEW REPUBLIC (May 29, 2014),
http://www.newrepublic.com/article/117898/lethal-injection-photos-angel-diazs-botched-executionflorida.
140. Id.
141. Chris Tisch, Doctor: Killing Flawed at Start, ST. PETERSBURG TIMES (Feb. 12, 2007),
http://www.sptimes.com/2007/02/12/news_pf/State/Doctor__Killing_flawe.shtml; see also Crair,
supra note 139.
142. Morales v. Tilton, 465 F. Supp. 2d. 972, 980 (N.D. Cal. 2006).
143. Ty Alper, supra note 137, at 41.
144. Order Following Remand at 2, Morales v. Cate, No. 5-6-cv-219-JF-HRL (N.D. Cal. 2010).
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2007, the U.S. Supreme Court granted certiorari to Baze v. Rees and
seemed poised to address this controversy. 146 However, the Court found
that there was insufficient reason to conclude that Kentucky’s lethal
injection protocol was unconstitutional, though it could reach agreement
on little else. 147
Since that time, much has changed. States are facing drug shortages,
drug embargoes, and ethical restrictions that may prevent qualified
experts from becoming involved in executions. The FDA recently began
regulating the importation of drugs for use in executions. 148 Drug
manufacturers, particularly those based in Europe, have raised concerns
that exportation of their drugs may result in those drugs being used for
executions. These manufacturers have either stopped selling their drugs
in American markets or specifically prohibited the use of their drugs in
executions. 149 Experiencing greater difficulties in obtaining drugs that
are already on the market for lethal injection purposes, state departments
of corrections are turning to compounding pharmacies to obtain the
drugs needed. 150 Compounding pharmacies are pharmacies that make
drugs to fill individual prescriptions, as opposed to the bulk
manufacturing of drugs by pharmaceutical companies. 151 The production
of drugs by compounding pharmacies has traditionally been much more
lightly regulated than the manufacturing of most prescription
medications. 152 The use of compounding pharmacies, however, has
undergone increased scrutiny after sixty-four deaths were attributed to
the use of contaminated drugs produced at the New England

145. See Denno, supra note 99, at 76–77.
146. Baze v. Rees, 551 U.S. 1192 (2007).
147. Linda Greenhouse, Justices to Enter the Debate Over Lethal Injection, N.Y. TIMES (Sept.
26, 2007), http://www.nytimes.com/2007/09/26/washington/26lethal.html?_r=0.
148. Kevin O’Hanlon, Company Recalls Nebraska’s Lethal Injection Drug, LINCOLN J. STAR
(May 9, 2012), http://journalstar.com/news/local/crime-and-courts/company-recalls-nebraska-slethal-injection-drug/article_3694f11a-a844-5955-ae7f-a5d9253ed10a.html.
149. See Proposal for a Regulation of the European Parliament and of the Council, COM (2014)
1 final (Jan. 1, 2014), available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=
COM:2014:0001:FIN:EN:PDF (prohibiting the exportation of drugs for use in capital punishment).
Additionally, manufacturers in the United States have made anti-capital punishment statements and
indicated that they will not sell drugs for use in executions. See, e.g., Anti-Capital Punishment
Statement, SAGENT PHARMACEUTICALS, http://www.sagentpharma.com/contactmenu/anti-capitalpunishment-statement.html (last visited Jan. 5, 2015).
150. Denno, supra note 27, at 1366.
151. Matt McCarthy, FDA Inspections Find Unsafe Practices in Compounding Pharmacies, 346
BMJ 1 (2013).
152. See id.
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Compounding Center. 153 Congress recently passed a law heightening
regulatory requirements for compounding pharmacies and for the
reporting of adverse events from their products. 154 This law also creates
a new category of regulated entities (“outsourcing facilities”) that
compounding pharmacies can fall under. 155 If a compounding pharmacy
voluntarily registers with the FDA as an “outsourcing facility,” certain
FDA requirements would be relaxed, but FDA inspections of their
facilities would be permitted. 156 It is not clear at present whether this law
will also apply to drugs obtained from compounding pharmacies that are
used in executions.
While many states are actively engaged in modifying their lethal
injection protocols, these protocols are not uniform across the country.
Different states use different drugs. Some states use midazolam, which is
used for treatment of seizures and as premedication for anesthesia, and
pentobarbital, a barbiturate commonly used to euthanize animals and to
treat seizures in humans. 157 Eleven states have modified their protocols
to allow for the possibility of execution with a single drug. 158 Because of
drug shortages, sixteen states substituted the drug pentobarbital for
sodium thiopental, the anesthetic they previously used. 159 Missouri also
switched to a one-drug protocol and initially selected the drug propofol,
but then later revised its execution procedures to require pentobarbital as
well. 160 Even after its protocol was determined to be constitutional in
Baze, Kentucky switched to a one-drug protocol, with a back-up of a

153. Stephen Barlas, New Congressional Bill Attempts to Aid Pharmacy Response to Drug
Shortages, 39 P&T 51, 51 (2014).
154. Drug Quality and Security Act, H.R. 3204, 113th Cong. (2013).
155. Erika Lietzan & Mingham Ji, Pharmacy Compounding After the Drug Quality and Security
Act, 26 HEALTH LAWYER 4–5 (2014).
156. Id. However, there is some concern that by passing this law, Congress may have actually
undermined the FDA’s regulatory authority because compounding pharmacies are not required to
register with the FDA, and FDA already had regulatory tools that it could apply to compounding
pharmacies that are taken away if compounding pharmacies register as outsourcing facilities. Id. at
5. Nonetheless, the new law does clarify that FDA has some authority over compounding
pharmacies, and this authority was arguably less clear before the law was passed.
157. Paul W. Shaw, Federal Legislative Response to the Controversy over Drug Compounding, 7
J. HEALTH & LIFE SCI. L. 84, 84 (2014).
158. See Denno, supra note 27, at 1359 chart 4.
159. See id.
160. See MO. DEP’T OF CORR., PREPARATION AND ADMINISTRATION OF CHEMICALS FOR LETHAL
INJECTION (2013) (on file with Washington Law Review) State by State Lethal Injection, DEATH
PENALTY INFO. CTR., http://www.deathpenaltyinfo.org/state-lethal-injection (last visited June 2,
2014).
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two-drug protocol if necessary. 161
In at least some cases, these changes have seemed to contribute to
botched executions. In October 2012, an execution in South Dakota used
compounded pentobarbital that was later found to be contaminated with
fungus. Eric Robert, the inmate executed with the adulterated drug, had
his eyes open throughout the execution, raising concern that he may not
have been adequately anesthetized. 162
The process of experimentation is well illustrated by what has
happened in Ohio. Ohio first allowed lethal injection in 1993 as a
possible alternative to electrocution, and retired its electric chair and
made lethal injection its sole method of execution in 2002.163 The
protocol in Ohio has changed several times. One of the most significant
changes occurred in 2009. Ohio switched to a one-drug protocol (with a
back-up plan) after an Ohio state court judge determined that the threedrug protocol violated Ohio’s statutory requirement for a “quick and
painless death.” 164 Although this change was a big departure from prior
protocols, it also was likely to decrease the risks of execution, and it
introduced an option that inmates had been requesting and may
reasonably have chosen in an informed consent process.165 The State
then switched from one barbiturate to another after a drug shortage, and
then moved to a two-drug protocol involving midazolam after the
Danish manufacturer of the barbiturate refused to sell it for use in
executions. 166 In 2013, Ohio introduced another new protocol that
included many changes from the previous protocols, including: (1) the
intravenous administration of two execution drugs—hydromorphone and
midazolam; (2) the use of compounded drugs; and (3) the availability of
multiple options if the preferred method of execution will not work for
some reason, including the possibility of intramuscular injection, which
no other state has used. 167 In this lethal injection protocol, the state also
added a quality assurance review with a designated official empowered
161. 501 KY. ADMIN. REGS. 16:330 (2012).
162. South Dakota Covers Up Source of ‘DIY’ Death Penalty Drugs Ahead of Execution,
REPRIEVE (Oct. 30, 2012), http://www.reprieve.org.uk/press/2012_10_30_South_Dakota_
execution_drugs.
163. Capital Punishment in Ohio, OHIO DEP’T OF REHABILITATION & CORRECTION,
http://www.drc.ohio.gov/public/capital.htm (last visited Jan. 5, 2015).
164. State v. Rivera, Nos. 04CR065940, 05CR068067, at 5 (Ohio Cnty. Ct. C.P. June, 10, 2008).
165. See infra Part IV.
166. Ben Crair, Exclusive Emails Show Ohio’s Doubts About Lethal Injection, NEW REPUBLIC
(Aug. 17, 2014), http://www.newrepublic.com/article/119068/exclusive-emails-reveal-statesworries-about-problematic-execution.
167. Denno, supra note 27, at 1354–58.
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to review the conduct of executions in consultation with others
(including a “properly trained medical person”), but it is not clear
whether or how this is being implemented. 168 In January 2014, an
execution was conducted under Ohio’s modified protocol that did not go
according to plan. Dennis McGuire’s execution lasted twenty-six
minutes, during which time he gasped, snorted, and appeared to be
struggling for breath. 169
Notably, the introduction of several untested components at once
makes it more difficult to determine what is responsible for problematic
executions. 170 As another example, Florida was the first state to use
midazolam, and did so in an execution that lasted much longer than
average. Although the warden checked to confirm that the inmate was
unconscious prior to authorizing the administration of the next drug, the
inmate made several movements after the warden made this
determination. To witnesses it appeared that he was not fully
anesthetized. 171 The drugs used were not based on prior experience in
animal euthanasia—indeed, there was very limited evidence for this
dramatic change. 172 Some lethal injection experimentation today
demonstrates a willingness to expose inmates to drugs that have never
been used in this way before, even though the risks are highly uncertain.
Like the troubling historical experiments I described in Part I, lethal
injection experimentation has not been based on the kind of careful
preparation and evidence gathering that should be done before exposing
humans to new and uncertain risks. As I will explain below, using new
drugs in humans requires a rigorous evidentiary foundation—one that
lethal injection lacks.
III.

FEATURES OF LETHAL INJECTION INVOLVING
RESEARCH

In this section, I argue that by testing novel drugs, drug combinations,
and doses in executions to see what will work, states are conducting a
type of biomedical research, albeit one that is poorly designed and lacks
168. STATE OF OHIO DEP’T OF REHAB. & CORR., ORC 2949.22, 2949.25 (Oct. 10, 2013) (on file
with Washington Law Review).
169. Holschuh, supra note 30.
170. Lazare, supra note 32.
171. Daily Mail Reporter & Reuters, William Happ Executed: Florida Executes Man Using
Untried Lethal Injection Drug, DAILY MAIL (Oct. 15, 2013, 6:20 PM), http://www.dailymail.co.uk/
news/article-2462115/William-Happ-executed-Florida-executes-murderer-using-untried-lethalinjection-drug.html.
172. Alper, supra note 137, at 41–42.

08 - Shah - final.docx (Do Not Delete)

2015]

EXPERIMENTAL EXECUTION

4/13/2015 11:51 AM

177

a solid basis in the available evidence. The flimsy evidence base for the
use of various drugs, drug combinations, and doses makes it very
difficult to predict the outcome of most executions today. That
executions by lethal injection involve poorly conceived research
suggests that states should adopt the safeguards that have been
developed for human subjects research for executions by lethal injection.
Current approaches to execution by lethal injection have been conducted
in a manner that allows for rigorous and independent oversight by
experts on research, that permits subjects to provide informed consent to
protect their own interests, and that minimizes risks where possible.
Furthermore, states should either adopt approaches that do have a
rigorous evidentiary basis, or, if that is not possible, conduct research
that is scientifically rigorous.
As I will further explain below, executions by lethal injection have
some features of different categories of medical practice and innovation.
Nevertheless, the most concerning features of experimental executions
are the untested uses of new drugs, drug combinations, and dosages that
can be understood as risky, poorly conceived research.
It is useful to look at lethal injection executions in this way because
scholars of research ethics and regulation have already thought through
related issues in the context of medical research and have designed
structures and safeguards to promote the autonomy, safety, and ethics of
research subjects. Importing research protections to the lethal injection
context may help reduce the number of error-prone and haphazard
executions that are receiving considerable public scrutiny.
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Table 1: Non-validated Practice, Quality Improvement/Control,
& Research
Relevant
Features of
Lethal Injection
Protocols

Category

Definition

Non-validated
Practice

Use of a new or
untested medical
intervention,
without good
reason to believe
it will work

Using drugs and
drug
combinations
that have never
been used for
causing death in
a single
execution

Conduct
systematic
research or use
one-drug
protocols, as in
animal
euthanasia

Quality
Improvement/
Control
(QI/QC)

Applying existing
knowledge or
practices to bring
about immediate
improvement of
care in local
settings

Procedures to
facilitate
administration of
injections and
test of
consciousness by
non-medically
trained personnel

If high risk:
Informed
consent,
independent
expert
oversight of
QI/QC
activities,
minimize risks

Research

Testing
intervention(s) to
develop
generalizable
knowledge for
future use

Using drugs
never used for
euthanasia, to
find method for
use in other death
row inmates

Informed
consent,
independent
expert
oversight of
research, risk
minimization

A.

Response

Lethal Injection Executions as Involving Non-validated Practice

Some aspects of lethal injection experimentation involve the use of
drugs and interventions that do not have a rigorous evidence base that
assures states they will safely and effectively cause death. These features
of lethal injection can be thought of as non-validated medical practice.
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Non-validated practice involves using an intervention that is new or
untested, without good reason to believe it will work. 173 As was
previously discussed, the Commission grappled with this distinction
while writing The Belmont Report and recommended that non-validated
approaches “should be . . . made the object of formal research at an early
stage in order to determine whether they are safe and effective.”174
Similarly, the World Medical Association’s Declaration of Helsinki, an
influential international code of ethics, states: “Medical research
involving human subjects must conform to generally accepted scientific
principles, be based on a thorough knowledge of the scientific literature,
other relevant sources of information, and adequate laboratory and, as
appropriate, animal experimentation.” 175 The practice of medicine
improves by first testing novel agents in animals and in vitro, and then
slowly introducing them in humans. 176 To the extent that execution by
lethal injection involves entirely novel uses of experimental medications,
reform of lethal injection should involve conducting careful and
systematic research.
The scientific paradigm governing the adoption of new interventions
was not used for lethal injection, 177 even though the first three-drug
protocol was invented by a physician who had doubts about whether it
would actually work, 178 and the first state legislature to adopt a lethal
injection protocol was concerned about the lack of sufficient research on
lethal injection. Preliminary animal and laboratory research and
extensive experience of euthanizing animals have not been appropriately
translated into executions of lethal injection in humans. 179 For instance,
paralytic agents like pancuronium bromide are not used and are actually
condemned as inhumane by veterinary and animal welfare experts for
fear they might mask an animal’s suffering. 180 Significantly, the state of
Texas rejected advice from a veterinarian about the use of single-drug
protocols, used to euthanize animals, for fear the public would object to
173. See THE BELMONT REPORT, supra note 69, at 3–4.
174. Id. at 4.
175. Declaration of Helsinki, para. 21, June 1964, available at http://www.wma.net/en/
30publications/10policies/b3/.
176. Carl Cohen, The Case for the Use of Animals in Biomedical Research, 315 NEW ENG. J.
MED. 865, 865–69 (1986).
177. John Greiner, Drug Execution Plan Suffers Senate Setback, DAILY OKLAHOMAN, Feb. 16,
1977, at 16.
178. Denno, supra note 99.
179. Ty Alper, Anesthetizing the Public Conscience: Lethal Injection and Animal Euthanasia, 35
FORDHAM URB. L.J. 817, 835–37 (2008).
180. Id. at 837.
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treating people as we treat animals. 181
One way to move to a more evidence-based approach is to draw on
related evidence and experience to develop protocols that one can have a
reasonable degree of confidence will work. In particular, states could
more carefully extrapolate from animal euthanasia protocols or
euthanasia protocols for humans developed in other jurisdictions.
Drawing from existing evidence is especially important when there are
ethical concerns about randomizing participants to different approaches
to collect data about their relative merits, as may be true for research to
develop safe and effective methods of execution. Gathering
observational data and any available data from other, related fields to
improve an approach over time may sometimes be the best that can be
done. There is extensive experience with animal euthanasia that has not
been translated to the lethal injection context. 182 This experience would
rule out the use of the three-drug cocktail, and may suggest adoption of
one-drug protocols. For drugs that have sufficient animal and laboratory
data already on relevant clinical experience, there are still questions
about how to translate those data into the use of the drugs for lethal
injection in humans. Nevertheless, the risks of the use of these drugs are
much better characterized, and much less than the risks associated with
drugs that are in widespread use in executions by lethal injection today.
There is also some clinical experience with drugs that could be used
for lethal injection protocols in other jurisdictions. Oregon, the
Netherlands, Belgium, and other jurisdictions have experience with
physician-assisted suicide and euthanasia, and have developed protocols
over time to ensure death can occur humanely. These may be the only
other examples of medical practice that involve interventions used to
cause death. 183 Justice Alito’s opinion in Baze attempted to cast doubt on
the use of one-drug protocols by citing a study that showed that a small
percentage of patients receiving one-drug protocols do not die. 184 But
one-drug protocols do eliminate the risk of excruciating pain, so more
doses of the drug can be given as a back-up plan without raising concern
about the risk that the protocol will not work. 185 Over time, the
experiences of physicians in administering these protocols in physician181. Id. at 817.
182. See id. at 817–18.
183. Overview of Euthanasia, KNMP, http://www.knmp.nl/medicijnen-zorgverlening/overig/
euthanasia (last visited Feb. 21. 2014 ) (Dutch Professional Trade Association of Pharmacists).
184. See Baze v. Reese, 553 U.S. 35, 68 (2008) (Alito, J., concurring).
185. Eric Burger, Lethal Injection and the Problem of Constitutional Remedies, 27 YALE L. &
POL’Y REV. 259, 317–18 (2009).
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assisted suicide in the Netherlands have been systematically collected
and published to improve the process. 186 However, one key problem in
translating from protocols used in the Netherlands is that these protocols
are intended to be administered with physicians overseeing the process.
Given the considerable controversy over physician participation in
executions by lethal injection,187 it is not clear these protocols can be
directly translated for use in American executions.
Alternatively, states could conduct preclinical laboratory and animal
testing of drugs that have not been used to cause death, and develop
some of the evidence needed to be able to justify the use of these drugs
in humans. Statistical methods are necessary to determine how large
trials should be to evaluate the safety and efficacy of lethal injection
protocols, and whether a particular design (e.g., a control arm) is
necessary. This option would require the assistance of individuals with
expertise in conducting clinical research and could not be done by
members of state departments of corrections alone.
However, there may be other barriers that prevent states from moving
to protocols that are based in evidence from animal euthanasia. For
example, one-drug protocols may be difficult to implement in some
states that are having difficulty obtaining certain drugs. Leaving aside
the relatively recent drug shortages and embargoes, it is puzzling why
state departments of corrections have not been systematic and careful in
attempting to improve such a controversial procedure. One charitable
interpretation is that prison officials may be unaware of scientific
methods, and the many constraints on the participation of medical
personnel in executions have prevented states from obtaining good
advice. Another possibility is that the lack of any systematic oversight
by courts on lethal injection procedures, at least until fairly recently, has
encouraged states to be as conservative as possible and stick to the threedrug protocol in an effort to avoid further litigation that might be
prompted by changes to protocols. The least charitable interpretation
may be that those involved in developing execution procedures, much
like the researchers who first began experimenting on prisoners, place
little value on how they treat someone who has been sentenced to be
186. Pieter V. Admiraal, [The responsible performance of euthanasia; observations on the
discussion of the subject] [Article in Dutch], 127 Ned Tijdschr Geneeskd, 964, 964 (May 28, 1983);
see also Personal Communication with Annemieke Horikx, Royal Dutch Society of Pharmacy
(KNMP) (May 12, 2014).
187. Compare Robert D. Truog, I. Glenn Cohen, & Mark A. Rockoff, Physicians, Medical
Ethics, and Execution by Lethal Injection, 311 J. AM. MED. ASS’N 2375 (2014), with Lawrence
Nelson & Brandon Ashby, Rethinking the Ethics of Physician Participation in Lethal Injection
Execution, HASTINGS CTR. REP., May–June 2011, at 28–29.

08 - Shah - final.docx (Do Not Delete)

182

WASHINGTON LAW REVIEW

4/13/2015 11:51 AM

[Vol. 90:147

executed. State departments of corrections therefore may have little
incentive to proceed cautiously, except in the sense that executions do
not appear inhumane and disturbing to the general public.
B.

Lethal Injection as Involving Research

In this Section, I analyze the extent to which current approaches
involve medical research. When lethal injections expose inmates to
uncertain risks of drugs that lack solid evidence for use in executions,
this activity is a type of research that is neither well designed nor
systematic. Rather, it is conducted in an attempt to learn how to conduct
future executions on other death row inmates. All states conducting
executions have inmates on death row, borrow and learn from one
another’s experiences, and tend to change their protocols by adopting the
same new drugs around the same time. 188 This suggests that states are
making modifications and experimenting with the goal of producing
knowledge from each individual execution to improve future executions.
There are several different regulatory definitions of medical research,
ranging from more to less restrictive. 189 The narrowest definitions, like
the definition used in the Department of Health and Human Services
Regulations, 190 fail to capture experimentation that is poorly designed
and not systematic. The broader definitions, like those used in the FDA’s
investigational new drug regulations and in state statutes and department
of corrections policies, more clearly apply to many different types of
research, including experimental execution. I argue below that FDA
regulations are the most appropriate to apply, but also that there are
barriers to enforcing any of these regulations.

188. Denno, Lethal Injection Chaos Post-Baze, supra note 27, at 1341 chart 1, 1358 chart 3.
189. See infra tbl.2.
190. 45 C.F.R. § 46.102(d) (2014). But see 21 C.F.R. § 56.102(c) (2014) (defining “clinical
investigation,” which the FDA considers to be synonymous with research, as “any experiment that
involves a test article and one or more human subjects, and that either must meet the requirements
for prior submission to the FDA . . . or the results of which are intended to be later submitted to, or
held for inspection by, the FDA as part of an application for a research or marketing permit”).
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Table 2: Regulatory, Statutory & Policy Definitions of Research

Narrower

Broader

Statute/Regulation/
Policy

Definition of Research

DHHS Regulations,
Bureau of Prisons
Regulations

“[A] systematic
investigation, including
research development,
testing and evaluation,
designed to develop or
contribute to
generalizable
knowledge”

FDA IND Regulations

Any use of a drug,
except for the use of a
marketed drug in the
course of medical
practice, in which a
drug is administered to
one or more human
subjects

State Statutes &
Department of
Corrections Policies

Much variation; many
simply prohibit “the use
of inmates for medical,
pharmaceutical, or
cosmetic
experimentation”

Although no court has directly addressed this issue, several different
regulations governing research might apply to execution by lethal
injection: (1) the Department of Health and Human Services (DHHS)
regulations governing research on prisoners; (2) the research regulations
of the Bureau of Prisons; (3) state departments of corrections regulations
governing research on prisoners; and (4) the FDA’s Investigational New
Drug (IND) regulations. I discuss these regulations in turn, and conclude
that the three types of regulations that are most applicable are state,
Bureau of Prisons, and FDA regulations. Bureau of Prisons and state
regulations may impose helpful safeguards, but may also make it
difficult to conduct experimental execution at all if certain provisions are
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applied according to a plain text reading. Finally, the FDA regulations
are probably the most appropriate for regulating lethal injection
experimentation, but the FDA may be reluctant to participate in review
of lethal injection executions, and it would be difficult for courts to
compel the agency to act.
First, both the DHHS regulations governing research on prisoners and
the Bureau of Prisoners regulations would likely not apply to lethal
injection experimentation. The DHHS regulations apply only to research
funded by the federal agencies that have signed on to those
regulations. 191 However, some states do reference the DHHS regulations
in their state regulations governing research on prisoners. 192 Those states
may have difficulty continuing lethal injection research without
addressing the safeguards discussed in Part VI, below. Additionally, the
DHHS regulations define research narrowly as “a systematic
investigation, including research development, testing and evaluation,
designed to develop or contribute to generalizable knowledge.” 193 To the
extent that lethal injection executions are not systematically conducted,
they may not fit this definition. Significantly, the regulations require that
the research risks must be “commensurate with risks that would be
accepted by nonprisoner volunteers”—which makes it hard to imagine
that lethal injection research could be approved under these regulations,
even if they did apply. 194
As I have argued elsewhere, state and department of corrections
regulations in several states could severely restrict or prohibit current
approaches to executions by lethal injection. 195 The Bureau of Prisons
regulations apply to research conducted within the Bureau of Prisons,
either by external researchers or by employees of the bureau. 196 These
Bureau of Prisons regulations refer to the definition used in the DHHS

191. Federal Policy for the Protection of Human Subjects (‘Common Rule’), U.S. DEP’T HEALTH
& HUMAN SERVS., http://www.hhs.gov/ohrp/humansubjects/commonrule/ (last visited Jan. 5, 2015).
Institutions that receive federal funding for research typically are required to sign Federal Wide
Assurances (FWAs), in which they promise that all research conducted by their institution will
abide by the protections in the DHHS regulations. If a State’s Departments of Corrections has an
FWA, then it is possible that the DHHS regulations should be applied to lethal injection
experimentation, and that the Office for Human Research Protection has the authority to enforce
deviations from those regulations.
192. See, e.g., Research Guidelines, N.C. DEP’T OF CORR. (Jan. 21, 2015),
https://www.ncdps.gov/Index2.cfm?a=000003,002391,002412,002456.
193. 45 C.F.R. § 46.102(d).
194. 45 C.F.R. § 46.305(a)(3)–(4).
195. See Shah, supra note 32.
196. 28 C.F.R. § 512.10 (2014).
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regulations governing research that was previously mentioned, and also
prohibit “medical experimentation, cosmetic research, or pharmaceutical
testing.” 197 Although the definition of research referenced in these
regulations is relatively narrow, the prohibition of medical
experimentation is much broader. As I argued in a previous paper, in the
absence of creative statutory interpretation, broad prohibitions on
medical experimentation or pharmaceutical testing would seem to rule
out lethal injection experimentation altogether.198 The additional
restrictions in the Bureau of Prisons regulations include that risks to
subjects have to be minimized, the risks must be “reasonable in relation
to anticipated benefits,” “the selection of subjects within any one
institution must be equitable,” and informed consent is generally
required to be obtained and documented. 199 One problem with applying
these regulations to executions is that the Bureau of Prisons may not be
amenable to such a reading of their regulations, and may be more
sympathetic to arguments that executions do not involve the conduct of
experimentation or research.
A recent paper argues that the FDA’s regulatory authority likely
extends to reviewing executions by lethal injection. 200 The FDA has
authority to review new drugs and protect patients and research subjects
through its Investigational New Drug (IND) regulations. 201 The IND
regulations apply broadly to the use of interventions without a solid
evidence base, and use the following definition of research: “Clinical
investigation means any experiment in which a drug is administered or
dispensed to, or used involving, one or more human subjects. For the
purposes of this part, an experiment is any use of a drug except for the
use of a marketed drug in the course of medical practice.” 202 As an
example of the broad reach of these regulations, the FDA has previously
asserted that the IND regulations would cover human cloning. 203 The

197. 28 C.F.R. § 512.11(a)(3).
198. Shah, supra note 32, at 1111.
199. 28 C.F.R. § 512.11(a)(4).
200. See JOHNS HOPKINS CLINIC FOR PUB. HEALTH L. & POL’Y, supra note 32, at 1–3. The
authors note that there are jurisdictional challenges because actions to enforce the Food, Drug &
Cosmetic Act (FDCA) must be brought by the government, but argue that death row inmates may
be able to argue for enforcement on the basis of their Fourteenth Amendment due process rights or
as an Eighth Amendment challenge. Id. at 3–4.
201. Richard A. Merrill, Human Tissues and Reproductive Cloning: New Technologies Challenge
FDA, 3 HOUS. J. HEALTH L. & POL’Y 1, 5 (“The protection of study subjects is a central objective of
the law that permits FDA to approve INDs and of the Agency’s own standards and procedures.”).
202. 21 C.F.R. § 312.3(b) (2014).
203. Rick Weiss, Human Clone Research Will Be Regulated: FDA Asserts It Has Statutory
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definition of research in the IND regulations is much more expansive
than the definition used in the DHHS regulations. 204 It would seem to
require that states either define their activities as medical practice or
submit an IND application to the FDA. As noted earlier, many states
expressly define their activities as outside the scope of medical practice.
Even for states that do not define lethal injection executions as outside
the practice of medicine, to the extent they are conducting medical
research, they are clearly operating not engaged in the practice of
medicine.
Under the IND regulations, sponsors and researchers have to submit
an application of their research protocol to the FDA for prior review of
safety, efficacy, and scientific merit. The FDA would have the authority
to insist upon review by an institutional review board (IRB) or to
suspend the activity by placing the investigation on what is known as a
“clinical hold.” 205 Under the regulations, if a state submitted a proposed
protocol to the FDA and fulfilled the regulatory requirements thirty days
before an execution, and the FDA failed to act, then the state could
proceed with the execution. 206
The FDA might be reluctant to take on this review. First, there is lack
of clarity about the right standard of review and how the FDA would
apply its own statutory authority to executions. Another problem is that
the FDA is required to determine whether drugs are safe and effective
under the Federal Food, Drug, and Cosmetic Act, 207 which may be an
impossible standard for executions to meet. In FDA v. Brown &
Williamson Tobacco Corporation, 208 the Supreme Court held that the
FDA could not assert its authority over tobacco products because the
FDA’s requirement to ensure drugs and devices are safe simply could
Authority to Regulate Attempts at Human Cloning, WASH. POST, Jan. 20, 1998, at A1. (quoting the
Lead Deputy Commissioner Michael Friedman’s claim that the FDA had the authority to regulate
cloning through the IND regulations based on “serious health and safety issues” for the mother and
cloned fetus).
204. 21 U.S.C. § 355 (2012).
205. 21 U.S.C. § 355(i)(3)(A).
206. JOHNS HOPKINS CLINIC FOR PUB. HEALTH L. & POL’Y, supra note 32, at 12.
207. 21 C.F.R. § 312.22(a) (2014) (“FDA’s primary objectives in reviewing an IND are, in all
phases of the investigation, to assure the safety and rights of subjects, and, in Phase 2 and 3, to help
assure that the quality of the scientific evaluation of drugs is adequate to permit an evaluation of the
drug’s effectiveness and safety. Therefore, although FDA’s review of Phase 1 submissions will
focus on assessing the safety of Phase 1 investigations, FDA’s review of Phases 2 and 3
submissions will also include an assessment of the scientific quality of the clinical investigations
and the likelihood that the investigations will yield data capable of meeting statutory standards for
marketing approval.”).
208. 529 U.S. 120 (2000)
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not be met by regulating tobacco products—the FDA would have to take
them off the market. 209 Because Congress had “foreclosed the removal
of tobacco products from the market,” the Court found that FDA
regulation of tobacco products would “plainly contradict Congressional
policy.” 210 Although one could argue that executions cannot be
conducted in a safe manner since the goal of an execution is to cause
death, what the FDA regulates depends on how the clinical investigation
is defined. To the extent that the goal of clinical investigations in
executions would be to determine whether the use of certain drugs
within executions could decrease the risks of suffering, the FDA could
presumably approve that research. Precluding the use of some drugs as
unacceptably risky would also not clearly contradict Congressional or
state policy. Therefore, the FDA does have room to regulate executions
without banning them altogether, and would not necessarily have to
contradict federal or state policy to do so.
Additionally, the FDA routinely judges the safety of drugs where
those drugs pose both risks and benefits to the individuals who are
taking them. But there is no clear benefit to inmates to undergo
executions, so the risks and benefits would have to be evaluated in some
other way. Given that the Supreme Court has not settled on one standard
for determining when the risks associated with lethal injection would be
unconstitutional, 211 it may be very difficult for the FDA to assess
whether the risks associated with lethal injection are acceptable. Yet, as I
argue below, the research regulations do provide clear guidance on the
need to minimize risks, which is one area where the FDA’s considerable
expertise could be invaluable.
If the FDA decides not to enforce the IND regulations, whether the
agency can be compelled to act is not settled. It depends on whether the
agency’s decision was discretionary or mandatory. In Heckler v.
Chaney, 212 the U.S. Supreme Court reviewed the FDA’s decision not to
exercise its authority under the Food, Drug, and Cosmetic Act 213 to
perform enforcement actions such as reviewing the safety and efficacy
of lethal injection drugs being distributed in interstate commerce,
affixing warning labels to the drugs, and seizing drugs that were to be
used in executions. 214 The Supreme Court has explained that under the
209.
210.
211.
212.
213.
214.

Id. at 135.
Id. at 137–39.
Baze v. Reese, 553 U.S. 35, 52 (2008).
470 U.S. 821, 824 (1985).
21 U.S.C. § 355 (2012).
Heckler, 470 U.S. at 824.

08 - Shah - final.docx (Do Not Delete)

188

WASHINGTON LAW REVIEW

4/13/2015 11:51 AM

[Vol. 90:147

Administrative Procedures Act, if an agency elects not to pursue that
action and exercise its coercive power, the action is “presumptively
unreviewable” by the courts. 215 The particular decision to enforce the
FDCA was committed to agency discretion by law, and the Court
concluded that the presumption was not overcome in that case.
Deference to the FDA was warranted.216 On the other hand, in Cook v.
FDA, 217 the D.C. Circuit held that the FDA’s jurisdiction over the
regulation of importation of lethal injection drugs into the country was
not discretionary, but mandatory. The FDA was therefore required to
inspect the importation of drugs and refuse admission to drugs that were
adulterated, misbranded, or unapproved for use in the United States. 218
Importantly, the IND regulations require the sponsor of the research
to submit an application to the FDA, 219 suggesting that this may not be
an action subject to discretion on the part of the sponsor of the research
at least. This requirement on sponsors does not necessarily imply,
however, that the FDA is required to enforce these regulations against
departments of corrections who are failing to comply. 220 Additionally,
though the FDA can grant exemptions to IND requirements, to meet
these exemptions, states would have to receive approval from an IRB
and would also have to ensure that the way the drugs are being
administered does not “significantly increase the risks” or “decrease the
acceptability of the risks.” 221 There is no indication that any of the states
conducting lethal injection have received IRB approval, and it would be
hard to argue that administration of anesthetic and paralytic drugs by
non-medically trained prison officials could do anything but
significantly increase the risks involved.
There are, additionally, policy reasons why the FDA may be reluctant
to regulate experimental executions and courts may find these reasons
persuasive. For instance, in Heckler v. Chaney, 222 the FDA
Commissioner explained that the FDA decided not to exercise
jurisdiction over lethal injection drugs because its jurisdiction over these

215. Id. at 828–32.
216. Id. at 837.
217. 733 F.3d 1 (D.C. Cir. 2013).
218. Id. at 10 (citing 21 U.S.C. § 381(a) (2012)).
219. 21 C.F.R. § 312.1(a) (2014).
220. 21 U.S.C. § 355(i) (2012). Note that citizens could petition the FDA to ask why the FDA is
not enforcing IND regulations or failing to respond to a protocol submitted by a state department of
correction under 21 U.S.C. § 10.30 (2012).
221. 21 C.F.R. § 312.2(b)(iii).
222. 470 U.S. 821 (1985).

08 - Shah - final.docx (Do Not Delete)

2015]

EXPERIMENTAL EXECUTION

4/13/2015 11:51 AM

189

drugs was not clear and capital punishment is a matter of criminal justice
with which it should not interfere. 223 He further stated that:
Were FDA clearly to have jurisdiction in the area, moreover, we
believe we would be authorized to decline to exercise it under
our inherent discretion to decline to pursue certain enforcement
matters. The unapproved use of approved drugs is an area in
which the case law is far from uniform. Generally, enforcement
proceedings in this area are initiated only when there is a serious
danger to the public health or a blatant scheme to defraud. We
cannot conclude that those dangers are present under State lethal
injection laws, which are duly authorized statutory enactments
in furtherance of proper State functions . . . . 224
The court in Cook v. FDA also took into account policy considerations
that might give reason to respect an FDA decision not to act. The court
noted that as a matter of statutory interpretation, courts can depart from
the plain text if it would lead to an “absurd” result.225 In Cook, the court
considered the FDA’s arguments that the agency was best positioned to
determine how to allocate its scarce resources under this authority. 226
But the FDA’s inability to regulate every article imported into the
country did not convince the court that the FDA should not examine the
subset of drugs at issue in lethal injection executions. In sum, the FDA’s
regulations are the most applicable, but there are several barriers to
enforcing these regulations, particularly if the FDA is not willing to do
so itself. State regulations, department of corrections policies, and the
Bureau of Prisons regulations would also apply, though it would be
difficult to approve experimental execution under these regulations.
C.

Lethal Injection as Involving Quality Improvement

State departments of corrections explicitly indicate in some cases that
their activities are a form of quality improvement or quality control. As I
will argue below, the distinction between quality improvement and
research does not have much normative significance, and I will not rely
on it heavily in my analysis of what should be done about experimental
executions. Nevertheless, it is worth explaining what aspects of
executions might count as quality improvement to forestall potential
223. Id. at 824.
224. Id. at 824–25.
225. Cook v. FDA, 733 F.3d 1, 9 (D.C. Cir. 2013) (citing United States ex rel. Totten v.
Bombardier Corp., 380 F.3d 488, 494 (D.C. Cir. 2004)).
226. Id. at 9.
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objections.
As an example of a state describing lethal injection modifications and
the related data collection as quality control, Ohio explicitly labels a
section of its protocol with the subtitle “Quality Assurance,” and has a
designated Special Assistant for Execution Policy and Procedures. The
Ohio protocol provides: “The Special Assistant shall evaluate the
performance of the Execution Team, review the conduct of courtordered executions and report to the Director of the Department. His or
her duties will consist of reviewing documentation, training, and
professional qualifications, to ensure compliance with the written policy
directive.” 227 Quality control “is designed to bring about the immediate
improvement of care in local settings,” 228 typically by applying existing
knowledge of practices that are within the standard of care. These
modifications can happen at just one institution or several. The line
between research and quality control typically turns on whether the
results of the investigation are intended to improve local practice or to be
disseminated more broadly—quality improvement is often characterized
by the quick feedback of the findings into the same setting that was
making the changes and studying them. 229 Even if the State of Ohio is
right to see its lethal injection experimentation as a form of quality
assurance or quality control, whether it should have increased ethical
safeguards depends on the level of risk.
To the extent that these quality control activities involve high risks,
the distinction between research and quality control is a distinction
without a difference. Furthermore, scholarship on research ethics and
regulations has begun to recognize that the classic distinctions between
treatment, research, and quality control are eroding as data collection is
increasingly a part of every medical encounter, and the important
normative questions therefore are about the level of risk involved for the
subjects of the data collection.230 As quality control activities involve
increasing amounts of risk, the ethical restrictions on quality control
activities come closer to those governing research, and informed consent
is typically required. 231 Since the normative value of distinguishing
227. STATE OF OHIO DEP’T OF REHAB. & CORR., supra note 168.
228. Mary A. Baily et al., The Ethics of Using QI Methods to improve Health Care Quality and
Safety, HASTINGS CTR. REP., July–Aug. 2006, at S1, S29.
229. Id. at S34.
230. Nancy E. Kass et al., The Research-Treatment Distinction: A Problematic Approach for
Determining Which Activities Should Have Ethical Oversight, HASTINGS CTR. REP., Jan.–Feb. 2013,
at S4, S5; Emily A. Largent, Steven Joffe, & Franklin G. Miller, Can Research and Care Be
Ethically Integrated?, HASTINGS CTR. REP., July–Aug. 2011, at 3738.
231. See Kass et al., supra note 230, at S6–7.
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lethal injection practices that might be appropriately considered quality
control activities from those that have aspects of medical research is not
clear, I will not rely on this distinction in this analysis.
If the evidence that seven percent of all executions by lethal injection
have been botched in some way is accurate, and if the risks associated
with error involve excruciating pain and suffering, it seems likely the
risks involved in execution by lethal injection are more than minimal
and deserve increased ethical protections (namely, informed consent and
independent review of the protocols). It is also relevant that prison
officials who have difficulty obtaining the drugs needed for executions
are turning to compounding pharmacies, given the extra risks associated
with the drugs produced in compounding pharmacies. 232
In sum, by using untested drugs, drug combinations, and doses,
executions by lethal injection involve poorly designed research. The
regulations that most clearly apply to executions by lethal injection are
FDA IND regulations, Bureau of Prisons regulations, and state laws and
department of corrections policies that have expansive definitions of
research. There may be significant barriers facing those who seek to
enforce these regulations as they apply to experimental executions, as I
have suggested above. However, the regulations do converge on several
protections that have interesting implications for experimental
executions. In the next section, I demonstrate how the safeguards that
are common across the regulations would apply to lethal injection
experimentation.
IV.

SPECIFIC ETHICAL AND REGULATORY SAFEGUARDS
FOR LETHAL INJECTION EXECUTION

There are three requirements common to all of the regulations
described above that should be applied to experimental execution: (1)
independent oversight, (2) risk minimization, and (3) informed
consent. 233
A.

Independent Oversight
Perhaps the most important of the research protections, and the way to

232. Jesse M. Boodoo, Compounding Problems and Compounding Confusion: Federal
Regulation of Compounded Drug Products and the FDAMA Circuit Split, 36 AM. J.L. & MED. 220,
221 (2010).
233. See 45 C.F.R. § 46, subpart C (2014); 21 C.F.R. § 50 (2014); 28 C.F.R. § 512.10 (2014);
Ezekiel J. Emanuel, David Wendler, & Christine Grady, What Makes Clinical Research Ethical?
283 J. AM. MED. ASS’N 2701, 2701 (2000).
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ensure that the other requirements are met, is independent expert review.
Independent oversight of research helps ensure that research is sound,
likely to yield generalizable results, and not unacceptably risky. A
critical component of rigorous oversight is having relevant expertise.
Prison officials cannot be allowed the discretion to experiment with
biomedical interventions on prisoners without oversight. Officials
devising execution protocols seek execution methods that courts will not
view as involving cruel and unusual punishment and that do not raise
public concern, but not necessarily methods that reduce risks as far as
possible. One of the difficulties with the current system, as I will argue
below, is that courts lack sufficient expertise to evaluate protocols and
develop appropriate safeguards.
There are at least four possible places where independent review of
lethal injection protocols could be performed: (1) Institutional Review
Boards (IRBs), (2) courts, (3) the FDA, and (4) a quality control panel
set up specifically at the prison. Some commentators have argued that
IRBs should review lethal injection protocols. 234 IRBs are required to
have at least five members, with at least one member whose expertise is
scientific and at least one member from non-scientific background, and
one member who is not affiliated with the institution. 235 The research
ethics literature is replete with criticism of IRBs for being overprotective
and focused on informed consent above all else. 236 Given how
conservative IRBs are about the risks of research, 237 it is safe to assume
that no IRBs in the United States have experience reviewing research
designed to result in death. Nevertheless, IRBs do have far more
experience reviewing research than the courts, and the regulatory
requirements are meant to ensure some degree of relevant expertise and
independence from the institution. Thus, if there are IRBs that have
extensive experience reviewing research that takes place in correctional
settings, these IRBs might have the general expertise to evaluate lethal

234. Koniaris et al., supra note 32.
235. 45 C.F.R. § 46.107.
236. Carol A. Heimer & JuLeigh Petty, Bureaucratic Ethics: IRBs and the Legal Regulation of
Human Subjects Research, 6 ANN. REV. L. SOCIAL SCI. 601, 605–06 (2010) (“[M]uch of the
literature on human subjects regulation asserts that IRBs have failed at the task of regulating human
subjects research.”); Taimur Saleem & Umair Khalid, Institutional Review Boards—a Mixed
Blessing, 4 INT’L ARCHIVES MED. 19, 20 (2011) (commenting that IRBs “represent an intrusion of
bureaucracy and excessive red tape into medicine to the extent of being ‘frustrating’, ‘consternating’
and ‘paternalistic for the researchers”); see also Beth Azar, Ethics at the Cost of Research?,
MONITOR ON PSYCHOL., Feb. 2002, at 38, 38.
237. See Seema Shah et al., How Do Institutional Review Boards Apply the Federal Risk and
Benefit Standards for Pediatric Research?, 291 J. AM. MED. ASS’N 476 (2004).

08 - Shah - final.docx (Do Not Delete)

2015]

EXPERIMENTAL EXECUTION

4/13/2015 11:51 AM

193

injection experimentation. Additionally, IRBs do sometimes use ad hoc
subject matter experts in situations where the complexity of a research
study requires additional input.
Courts have, of course, already been involved in the process of
evaluating lethal injection protocols. One problem with having courts
review lethal injection protocols as research or quality control projects is
they typically have less expertise in evaluating research. Some of the
most prominent cases in which courts have made judgments pertaining
to research studies have been criticized for the limited understanding of
the justifications for and constraints on research. 238 The limitations faced
by courts are illustrated by the transcript of a hearing in the recent
Arizona execution of Mr. Wood discussed in the introduction. Although
the judge demonstrated impartiality and competence in running the
proceedings, because he did not know or have ready access to
information that brain death is incompatible with spontaneous breathing,
or whether stopping the execution would minimize the amount of pain
the inmate may have been suffering, the court’s ability to provide
adequate oversight over the execution was compromised. 239
There are legal procedures for hearing and evaluating scientific
evidence and expert testimony, including ensuring there is a zealous
advocate to present and vet the appropriate evidence. But the current
level of secrecy that many states are using with respect to their execution
procedures and suppliers is incompatible with robust independent review
of the research on lethal injection. If courts are not weighing evidence on
whether a particular compounding pharmacy has sufficient quality
control, or about the risks of the specific drugs that are being used, they
cannot conduct rigorous independent scrutiny of lethal injection
research. This secrecy has been justified based on concerns that death
penalty opponents will protest or harass those involved with executions,
but makes it difficult to feel confident that courts are providing sufficient
oversight. 240
Another possibility, as discussed in Part III above, would be for the
FDA to review executions by lethal injection. Under the FDA

238. See, e.g., Jack Schwartz, The Kennedy Krieger Case: Judicial Anger and the Research
Enterprise, 6 J. HEALTH CARE L. & POL’Y 148, 152–53 (citing Grimes v. Kennedy Krieger Inst.,
Inc., 782 A.2d 807 (Md. 2001)).
239. See generally Transcript of Telephonic Motion for Emergency Stay of Execution, Wood v.
Ryan, No. CV 14-1447-PHX-NVW (D. Ariz. July 23, 2014), available at http://www.scribd.com/
doc/234993495/Transcript-related-to-Joseph-Wood-execution.
240. Michael Graczyk, Texas Agency Pushes to Keep Execution Drug Source Secret, NEWSOK
(Apr. 2, 2014), http://newsok.com/texas-pushes-to-keep-execution-drug-source-secret/article/3949442.

08 - Shah - final.docx (Do Not Delete)

194

WASHINGTON LAW REVIEW

4/13/2015 11:51 AM

[Vol. 90:147

regulations, the FDA would review an IND application and would
require that an IRB review the research at the same time. 241 The FDA
may be reluctant to review executions, particularly without a clear sense
of what risk standard to apply. Unlike the courts, however, the FDA has
expertise in reviewing research, medical practice, and non-validated uses
of drugs and devices. The FDA has considerable scientific expertise and
is likely to be the body that is best informed about how the drugs being
used for lethal injection work and what risks are associated with them. It
is likely that the depth of expertise available at the FDA far surpasses
what an individual court can bring to bear on the questions surrounding
lethal injection. The FDA might be well situated to review lethal
injection experimentation.
Finally, it is possible that special institutional bodies could be set up
to review the quality control activities of various prisons. This approach
has the advantage of ensuring that people who have the relevant
expertise would be the ones reviewing the activities. Such a board might
include scientists who conduct research, former prisoners, lawyers, and
ethicists. One concern about this board is that it might be subject to
capture by advocates from either side of the death penalty debate. It
might therefore be advisable that some independent institution, such as
the judicial branch, be involved in vetting the board members,
analogously to the judicial use and oversight of special masters in
consent decrees. 242
Given the special expertise, authority, and independence of the FDA,
it seems clear that the FDA is at this time best positioned to review
experimentation in executions by lethal injection. A specially constituted
institutional board that has relevant expertise may be an alternative or an
addition to FDA review.
B.

Minimizing Risk

Both research and quality control activities are subject to the
requirement to minimize risk. Judging the risk level of research on
methods of execution by lethal injection requires comparing an
241. 21 C.F.R. § 312.66 (2014).
242. Wayne D. Brazil, Special Masters in Complex Cases: Extending the Judiciary or Reshaping
Adjudication?, 53 U. CHI. L. REV. 394, 394–95 (1986) (“Courts appoint special masters as a means
of addressing three overlapping categories of problems: judicial limitations, shortcomings of the
traditional adjudicatory system, and shortcomings of parties and counsel. Judicial limitations
include time constraints; lack of expertise in esoteric or technologically sophisticated areas; lack of
skill in certain roles, such as the facilitation of settlement negotiations; and limitations that stem
from the proprieties of judicial conduct, at least for the judge who will try the case.”).
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experimental execution to a standard execution. The risk of death is
therefore not a risk of the research—death is actually, in this case, the
desired outcome. The benefits might have to do with having shorter
executions that are more likely to be humane (perhaps analogous to the
benefits in palliative care research conducted at the end of life). Those
individuals who are being experimented upon should not be exposed to
any unnecessary risk that could easily be eliminated. The risk that seems
most relevant in analyzing executions by lethal injection is the risk of
pain and suffering before death, both in terms of its severity and its
duration. In other words, a long, drawn-out execution with significant
pain might be as concerning as a shorter execution that subjected an
inmate to pain of greater intensity.
In the case of In re Kemmler, the Court clarified that to violate the
Eighth Amendment, there must be “something inhuman and barbarous,
something more than the mere extinguishment of life.” 243 Although it is
clear that torture is beyond the pale, what degree of risk of a torturous
death the Eighth Amendment will tolerate is an open question. The
standards for weighing acceptable risks in research are similar, in some
respects, to the approach the Supreme Court has taken in defining what
risks of pain and suffering would be unconstitutional. As the Court
explained in Francis v. Resweber, 244 “The traditional humanity of
modern Anglo-American law forbids the infliction of unnecessary pain
in the execution of the death sentence. Prohibition against the wanton
infliction of pain has come into our law from the Bill of Rights of 1688.
The identical words appear in our Eighth Amendment.” 245 It has also
been recognized that an Eighth Amendment analysis requires analyzing
the objective risk of harm, and if that risk is significant enough, prison
officials cannot claim that they were “subjectively blameless” for harm
that would otherwise violate the Eighth Amendment. 246
However, how a court should weigh the objective risk of harm
became somewhat muddied in Baze v. Rees. There, a plurality of the
Court noted that the Supreme Court has shied away from providing a
precise definition of the Eight Amendment’s prohibition on cruel and
unusual punishment. The plurality approvingly quoted a case from 1879,
which noted that difficulty would attend the effort to define “with
exactness the extent of the constitutional provision which provides that

243.
244.
245.
246.

136 U.S. 436, 447 (1890).
Louisiana ex rel. Francis v. Resweber, 329 U.S. 459 (1947).
Id. at 463.
Farmer v. Brennan, 511 U.S. 825, 842, 846 n.9 (1994).
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cruel and unusual punishments shall not be inflicted;” but “it is safe to
affirm that punishments of torture, . . . and all others in the same line of
unnecessary cruelty, are forbidden” by that amendment to the
Constitution. 247 As Deborah Denno has argued, “the Court lacks a
coherent constitutional standard for assessing pain. Although the
gratuitous infliction of pain is definitely impermissible, far less clear is
the constitutionally allowable amount of pain that can exist for an
execution and the penological theory that might justify such pain.” 248
In Baze, the different opinions argued for different standards: (1) the
plurality indicated that a lethal injection protocol is not “cruel and
unusual” unless it involves a “substantial risk of serious harm” or an
“objectively intolerable risk of harm” and there are alternatives that
effectively address this risk; 249 (2) Justice Thomas argued that
executions violate the Eighth Amendment only when protocols are
“deliberately designed to inflict the pain”—thereby arguing for a focus
only on the subjective prong of an Eighth Amendment analysis; and (3)
Justice Ginsburg’s dissent (joined by Justice Souter) argued for a
standard that rules out an “untoward, readily avoidable risk of inflicting
severe and unnecessary pain.” 250 Justice Ginsburg’s dissent requiring
that there be no “untoward risk” 251 was the only standard that was
consistent with the obligation to minimize risks in research or quality
control activities. Thirty-six cases have cited Justice Ginsburg’s dissent
in an attempt to establish that, even under the strictest standard laid out
in Baze, the protocol in question would be considered constitutional. 252
Noting the Court’s inability to agree on a particular standard, as well as
the considerable changes that have been made to lethal injection
protocols (even the Kentucky protocol approved in Baze has been
changed to a one-drug protocol), Denno has argued that the precedent set
in Baze is largely moot. 253
Practically, risk minimization likely puts extra scrutiny on particular
aspects of execution by lethal injection. For instance, risk minimization
may require Departments of Corrections to stop using the drug
247. Baze v. Rees, 553 U.S. 35, 48 (2008) (quoting Wilkerson v. Utah, 99 U.S. 130, 136 (1879)).
248. Deborah W. Denno, Getting to Death: Are Executions Constitutional?, 82 IOWA L. REV.
319, 326 (1997).
249. Baze, 553 U.S. at 50, 52.
250. Id. at 52 (plurality opinion); id. at 94 (Thomas, J., concurring); id. at 123 (Ginsburg, J.,
dissenting).
251. Id. at 123 (Ginsburg, J., dissenting).
252. Denno, supra note 27, at 1353.
253. Id. at 1346.
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midazolam (which was implicated in three of the four botched
executions that occurred in 2014), 254 intramuscular injections, paralytic
agents, and compounding pharmacies. Additionally, securing the
involvement of physicians would be an important way to minimize the
risks to which inmates are exposed.
Some state protocols permit intramuscular injection, which is also
unnecessarily risky. 255 Individuals who receive intramuscular injections
may experience wide variation in how quickly the drug is taken up by
their bodies, and may therefore suffer extended executions and increased
exposure to painful side effects. 256 Given the possibility of faster-acting
intravenous injection, this risk may not be necessary. The use of
compounding pharmacies adds to the risk, since it is possible that
incorrect drugs or dosages will be used, or that the drugs will be
contaminated. Finally, despite the controversy it would raise, it seems
likely that the involvement of medically trained professionals may also
decrease the risks associated with lethal injection.257
The use of paralytic agents fails scrutiny under a standard requiring

254. See Missouri Used Controversial Execution Drug Midazolam, Report Finds, THE
GUARDIAN (Sept. 3, 2014, 4:15 PM), http://www.theguardian.com/world/2014/sep/03/missouriexecution-drug-sedative-midazolam-report.
255. See, e.g., STATE OF OHIO DEP’T OF REHAB. & CORR., supra note 168.
256. Declaration of Mark J.S. Heath, M.D. at 6–9, Cooey (Biros) v. Strickland, No. 2:04cv1156GLF-MRA (S.D. Ohio. Dec. 3, 2009).
257. The American Medical Association has an ethical prohibition on physician involvement in
executions, and there is considerable debate over whether physicians should participate in
executions by lethal injection in the scholarly literature. See, e.g., AM. MED. ASS’N, CODE OF
ETHICS OPINION 2.06 – CAPITAL PUNISHMENT (2005); Ty Alper, The Role of State Medical Boards
in Regulating Physician Participation in Executions, 95 J. MED. LICENSURE & DISCIPLINE (2009),
available at http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1544623; Linda L. Emanuel,
Letter: Physicians and Executions, HASTINGS CTR. REP. Mar.–Apr. 2012, at 4; Lawrence Nelson &
Brandon Ashby, Rethinking the Ethics of Physician Participation in Lethal Injection Execution,
HASTINGS CTR. REP., May–June 2011, at 28, 29; Robert D. Truog & Troyen A. Brennan,
Participation of Physicians in Capital Punishment, 329 NEW ENG. J. MED. 1346, 1348 (1993);
Robert D. Truog, I. Glenn Cohen, & Mark A. Rockoff, Physicians, Medical Ethics, and Execution
by Lethal Injection, 311 J. AM. MED. ASS’N 2375 (2014); Robert M. Veatch, The Impossibility of a
Morality Internal to Medicine, 26 J. MED. & PHIL. 621, 634 (2001); David Waisel, Physician
Participation in Capital Punishment, 82 MAYO CLINIC PROC. 1073, 1079 (2007). Notwithstanding
this debate, some physicians clearly do participate in executions without fear of legal sanction. See,
e.g., Ty Alper, The Role of State Medical Boards in Regulating Physician Participation in
Executions, 95 J. MED. LICENSURE & DISCIPLINE 1, 3 (2008) (noting that states have indicated that
physicians were involved in overseeing executions and have even taken more active roles, and that
legal prohibitions are unlikely to be enforced); Denno, supra note 99, at 65–70 (explaining that
physicians have been involved in executions since the creation of the first lethal injection protocol
in Oklahoma); Atul Gawande, When Law and Ethics Collide—Why Physicians Participate in
Executions, 354 NEW ENG. J. MED. 1221, 1223–28 (2006) (interviewing physicians who indicated
that they have participated in executions for various reasons).
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risk minimization. These agents mask any movements or distress by the
inmate, making it impossible to tell if the inmate has not been properly
anesthetized. The justification for a paralytic agent is to further the
state’s interest in dignity by maintaining an appearance of a peaceful
death. Although the state might have some reason to modify executions
to make them seem more dignified, there should be a limit on the level
of risk involved. For instance, the use of blankets to cover an inmate’s
limbs might be one way a state could make an execution appear more
dignified without increasing risk. On the other hand, if a state were to
argue that having to submit to lethal injection challenges in the courts
and share information about executions publicly limits the dignity of the
procedure, this would seem to give the interest in dignity far too much
weight. Because it could pose significant risk, the use of a paralytic
agent does not seem justifiable by an interest in dignity, and therefore
fails to fulfill the obligation to minimize risks in research.
C.

Informed Consent

Another requirement for the ethical conduct of research is informed
consent. Valid informed consent would require disclosure of the drugs
and procedures being used, the risks involved, and the available
alternatives. Obtaining informed consent helps ensure that people are not
subjected to experimentation unknowingly or against their will and that
they are able to protect their own interests.258 Asking for informed
consent from inmates could also help ensure that lethal injection
protocols are not excessively risky for particular inmates with special
conditions. For instance, Russell Bucklew’s execution has been placed
on hold by the Supreme Court because he has a unique medical
condition, referred to as cavernous hemangioma, which causes him to
have clumps of malformed blood vessels that would greatly increase the
risks of a prolonged and painful execution. 259
As the Institute of Medicine’s Committee on Ethical Considerations
for Protection of Prisoners Involved in Research stated, “ethical research
involves ensuring, as a prerequisite for research, that the standard of
medical health care available in the correctional setting permits the
inmate to have a meaningful choice between the existing care that is
available and the experimental intervention.”260 Inmates do not, of
258. Emanuel, Wendler & Grady, supra note 233, at 2706.
259. John Eligon, Supreme Court Halts Missouri Execution and Sends Case Back to Appeals
Court, N.Y. TIMES, May 22, 2014, at A16.
260. ETHICAL CONSIDERATIONS, supra note 93, at 22.
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course, have the right to give informed consent to being executed—that
decision is for a jury to make. Instead, just as some inmates might be
given a choice to participate in research conducted by the state testing a
new medication for treating HIV, so too should inmates be asked for
their consent to participate in research about how they should be killed.
As previously discussed, consent is required for quality control
procedures that involve more than minimal risk, and is typically required
for many categories of research.
States seeking to modify their lethal injection protocols would have to
ask inmates whether they prefer the modified or unmodified version of
the protocol or could offer inmates a choice of a different method of
execution altogether. This is not a wholly unprecedented suggestion.
Great Britain’s Royal Commission on Capital Punishment reviewed
lethal injection in the middle of the twentieth century and noted that,
although lethal injection raised too many concerns for them to
recommend its immediate adoption, an anesthetist testifying before the
Royal Commission suggested that: “It should be offered as an
alternative, pleasanter, method of execution, and should be used only
when it has been willingly accepted.” 261 The Royal Commission was
concerned that inmates might have a hard time making such a decision,
and also believed that it was the State’s responsibility to select the best
method of execution available and carry it out with “dignity, solemnity,
speed, and certainty.” 262
Nevertheless, some states do offer inmates a choice between different
methods of execution. Florida’s statute provides that a person sentenced
to death will undergo lethal injection, unless he or she “affirmatively
elects to be executed by electrocution.” 263 Missouri permits execution
261. ROYAL COMM’N ON CAPITAL PUNISHMENT, supra note 124, at 259.
262. Id.
263. FLA. STAT. § 922.105(1) (West, Westlaw through Ch. 255 (End) of 2014 2d Reg. Sess. &
Sp. “A” Sess. of 23d legislature); see also South Carolina: “A person convicted of a capital crime
and having imposed upon him the sentence of death shall suffer the penalty by electrocution or, at
the election of the person, lethal injection under the direction of the Director of the Department of
Corrections. The election for death by electrocution or lethal injection must be made in writing
fourteen days before the execution date or it is waived. If the person waives the right of election,
then the penalty must be administered by lethal injection.” S.C. CODE ANN. § 24-3-530(A)
(Westlaw through end of 2014 Reg. Sess.); Tennessee: noting that if other methods become
unavailable for some reason, an inmate no longer has the right to choose and “all persons sentenced
to death for a capital crime shall be executed by any constitutional method of execution,” TENN.
CODE ANN. § 40-23-114 (Westlaw through end of 2014 2d Reg. Sess.); Utah: allowing some
inmates to opt for death by firing squad, UTAH CODE ANN. § 77-18-5.5 (Westlaw through 2014
General Sess.); Virginia: “The Director, or the assistants appointed by him, shall at the time named
in the sentence, unless a suspension of execution is ordered, cause the prisoner under sentence of
death to be electrocuted or injected with a lethal substance, until he is dead. The method of
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either by lethal injection or in a gas chamber. 264 By contrast, in twentyone states, lethal injection is the only execution method allowed. 265
Some states could reinstate older methods of execution to offer
alternatives. 266 Of course, alternative approaches to execution may not
be available if they have been ruled unconstitutional, so the only
alternative in such jurisdictions would be an unmodified lethal injection
protocol. 267 If there are states where there are truly no alternative
options, it may still be worthwhile to provide inmates with the
information about the protocol to see if there are any particular risks that
can be minimized—for instance, if a larger dose of the anesthetic might
be needed for an inmate who previously suffered from drug addiction.
Simply informing inmates about what they will be given may be an
important protection for inmates who have special medical conditions
that make the planned doses or drugs especially risky for them. 268
Significantly, inmates are likely to give consent to at least some
execution shall be chosen by the prisoner. In the event the prisoner refuses to make a choice at least
fifteen days prior to the scheduled execution, the method of execution shall be by lethal injection.
Execution by lethal injection shall be permitted in accordance with procedures developed by the
Department.” VA. CODE ANN. § 53.1-234 (Westlaw through end of 2014 Reg. Sess. & includes cc.
1 to 5 from the 2014 Sp. S. I.); Washington: “The punishment of death shall be supervised by the
superintendent of the penitentiary and shall be inflicted by intravenous injection of a substance or
substances in a lethal quantity sufficient to cause death and until the defendant is dead, or, at the
election of the defendant, by hanging by the neck until the defendant is dead. In any case, death
shall be pronounced by a licensed physician.” WASH. REV. CODE § 10.95.180(1) (2014).
264. MO. REV. STAT. § 546.720(1) (Westlaw through end of 2014 2d Reg. Sess. of 97th General
Assembly). In an analysis of different methods of execution conducted in the mid-twentieth century,
Great Britain’s Royal Commission on Capital Punishment dismissed lethal gas as an option because
of the “highly unpleasant historical associations” with lethal gas that might render this method of
execution unpalatable to the public. ROYAL COMM’N ON CAPITAL PUNISHMENT, supra note 124, at
257.
265. Denno, supra note 27, at 1342 (current information as of June 2014). See, e.g., KY. STAT.
ANN. § 431.220(1)(a) (Westlaw through end of 2014 legis.) (“every death sentence shall be
executed by continuous intravenous injection of a substance or combination of substances sufficient
to cause death”).
266. David Stout, The Tennessee Senate Has Backed a Bill to Reinstate the Electric Chair, TIME
(Apr. 10, 2014), http://time.com/57066/tennessee-senate-electric-chair-capital-punishmentexecution/.
267. For instance, the Ninth Circuit has ruled that gas chamber executions are unconstitutional.
See Fierro v. Gomez, 77 F.3d 301, 309 (9th Cir. 1996).
268. See, e.g., Bucklew v. Lombardi, 565 F. App’x 562, 564 (8th Cir. 2014) (Granting a stay of
execution after agreeing that the evidence demonstrated that Bucklew “suffers a medical condition
known as cavernous hemangioma involving large vascular deformities and tumors in his face and
neck that cause pressure, pain, and frequent bleeding” that was likely to result in “either (1) a long,
drawn-out, and painful death due to poor movement of the drug through his atypical circulatory
system, or (2) death via choking and suffocation on blood released by anticipated ruptures of the
weakened veins in his neck and face.”); stay subsequently granted in Bucklew v. Lombardi,
__ U.S __, 134 S. Ct. 2333 (2014).
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protocols. Ohio’s brief move to a one-drug protocol was what inmates
had been requesting in prior litigation because it was likely to decrease
risks. 269
There is, however, an important issue to resolve in obtaining informed
consent for executions. Under Stewart v. LeGrand, 270 the Supreme Court
held that if an inmate elects a particular method of execution, he waives
his right to challenge its constitutionality. 271 In the canons of research
ethics, the function of requiring informed consent in research is to ensure
that individuals can protect their own interests and exercise their
autonomy. 272 The FDA regulations and the DHHS regulations indicate
that informed consent cannot serve as a waiver, stating as follows: “No
informed consent, whether oral or written, may include any exculpatory
language through which the subject or the representative is made to
waive or appear to waive any of the subject’s legal rights, or releases or
appears to release the investigator, the sponsor, the institution or its
agents from liability for negligence.” 273
In the lethal injection context, informed consent can help ensure that
the options that minimize risks are offered to inmates, the changes made
to protocols do not increase the risks, and that inmates with particular
conditions that increase the risks are identified in advance. These
protective functions could be watered down if inmates were wary of
electing one option over another because it foreclosed future legal
challenges. Given the state of flux in lethal injection protocols, it also
seems important to preserve an ongoing right to challenge a protocol
when evidence emerges about new risks or better alternatives.
Inmates would have to be informed what drugs were being used in the
modified and unmodified protocols to make an informed choice. That
disclosure would violate the secrecy some states now maintain. Much of
the experimentation being conducted is not transparent. A Texas
appellate court recently permitted the Department of Corrections to keep
secret the name of the compounding pharmacy producing the drugs they
will use in an upcoming execution. 274 The court reasoned that revealing
269. See generally State v. Rivera, Nos. 04CR065940, 05CR068067 (Ohio Cnty. Ct. C.P. June
10, 2008).
270. 526 U.S. 115 (1999).
271. Id. at 119 (1999); see also State v. Morris, 24 S.W.3d 788, 797 (Tenn. 2000).
272. Ezekiel J. Emanuel, David Wendler, & Christine Grady, What Makes Clinical Research
Ethical?, 283 J. AM. MED. ASS’N 2701, 2706 (2000).
273. 21 C.F.R. § 50.20 (2014); 45 C.F.R. § 46.116 (2014) (general requirements for informed
consent).
274. Michael Graczyk, Appeals Court: Texas Execution Back On, BIG STORY (Apr. 7, 2014),
http://bigstory.ap.org/article/appeals-court-texas-execution-back.

08 - Shah - final.docx (Do Not Delete)

202

WASHINGTON LAW REVIEW

4/13/2015 11:51 AM

[Vol. 90:147

the names of these pharmacies subjects them to pressure and protests
from anti-death penalty groups. One Associated Press investigation
found that all but four states refused to disclose the source of their lethal
injection drugs. 275 Thus, informed consent is an important protection that
many states could easily incorporate, but that is incompatible with the
level of secrecy in some states.
CONCLUSION
By using new drugs, novel drug combinations, and untested doses,
executions by lethal injection involve medical experimentation that is
neither well designed nor evidence based. Executions have not adhered
to the standards of validating medical practice, which would require
careful extrapolation from existing data and/or rigorous data gathering in
humans to find an effective approach that does not exceed the Eighth
Amendment’s restrictions on risks of pain and suffering. States have also
failed to take account of the principles and legal requirements governing
biomedical research, including obtaining independent review, informed
consent, and minimizing risks. Adherence to those principles would
protect inmates against excessive and unnecessary risks.
Some readers may be concerned that these arguments are merely a
cover for an abolitionist view on the death penalty. Because certain
lethal injection drugs are in short supply, adherence to the principles of
biomedical research may be very difficult. The logical conclusion might
be to halt executions by lethal injection. While it is possible that
abolitionists will find some of the arguments made here congenial to
their views, it is also possible that this Article provides a framework for
more humane lethal injections that may be more acceptable to courts and
the general public. The goal of this paper is not to spell out better ways
to perform lethal injection, but to make clear how to understand lethal
injection experimentation and how to regulate it. In particular, this
analysis may help ensure that the current practice of lethal injection is
properly regulated so that it no longer involves scientifically
questionable, disrespectful, and risky experimentation on inmates. Death
penalty proponents have shown resourcefulness in responding to lethal
injection challenges, 276 as have abolitionists, 277 and it would be
275. Andrew Welsh-Huggins & Jim Salter, In Most States, Execution Drugs Are Surrounded By
Secrecy, HUFFINGTON POST (Apr. 5, 2014), http://www.huffingtonpost.com/2014/04/05/executiondrugs-secrecy_n_5097069.html.
276. Mark Berman, Missouri Attorney General Wants the State to Produce its Own Lethal
Injection Drugs, WASH. POST (May 29, 2014), http://www.washingtonpost.com/news/post-nation/
wp/2014/05/29/missouri-attorney-general-wants-the-state-to-produce-its-own-lethal-injection-drugs.
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overstating the case to imagine that this Article could end the debate
over executions by lethal injection one way or the other.
It is possible that challenges to lethal injection will push states to
revert to other methods of execution that have been used in the past,
including firing squads, hanging, electrocution, and lethal gas. Many of
these options raise concerns beyond the scope of the present paper. 278
However, it is worth noting that the FDA regulates the use of anesthetic
gas, and it is sometimes used as a medical intervention. 279 For this
reason, the use of the gas chamber may be subject to FDA oversight and
might face challenges similar to those I have discussed here.
Future research on experimental executions should address what
causes of action might be available to prisoners to challenge lethal
injection executions as involving the conduct of research. Other
questions include whether families of inmates in executions gone wrong
can obtain damages from the state—and whether alternatives like the use
of lethal gas might raise similar concerns about the conduct of research.
My analysis has also revealed gaps in research ethics and regulation.
Many scholars have noted that there are significant gaps in the
regulation of research in the absence of federal funding. 280 Less explored
are gaps in regulation of poorly conducted and secretive research. If
biomedical research is systematic and rigorous, it should clearly be
regulated. If, however, biomedical research is poorly designed and

In addition, proposals for a new method have sometimes come from unusual quarters. See Tracy
Connor, Jack Kevorkian’s Aide Pushed Carbon Monoxide for Executions, NBC NEWS (May 29,
2014, 11:36 AM), http://www.nbcnews.com/storyline/lethal-injection/jack-kevorkians-aide-pushedcarbon-monoxide-executions-n117806.
277. Holly Williams, Meet the Woman Behind a Shortage of Execution Drugs, CBS NEWS, (Apr.
30, 2014, 7:31 PM), http://www.cbsnews.com/news/meet-the-woman-behind-a-shortage-ofexecution-drugs/.
278. See Robert J. Sech, Hang ‘Em High: A Proposal for Thoroughly Evaluating the
Constitutionality of Execution Methods, 30 VAL. U.L. REV. 381 (1995). See generally Christopher
Q. Cutler, Nothing Less than the Dignity of Man: Evolving Standards, Botched Executions and
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cloaked in secrecy, it becomes much more difficult to determine how to
regulate it, and even the avenues suggested here may depend on
voluntary action by an agency like the FDA. This regulatory gap exists
even though concerns about risks and uncertainty might increase in
research that is not well designed, evidence-based, conducted by experts,
or transparent. The origins of and solution to this paradox of research
ethics and regulation are critically important avenues for future research.

